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ABSTRACT OF DISSERTATION 
 
 
FUNCTIONAL ROLES FOR POST-TRANSLATIONAL MODIFICATIONS OF 
t-SNARES IN PLATELETS 
 
Platelets affect vascular integrity by secreting a host of molecules that promote 
hemostasis and its sequela. Given its importance, it is critical to understand how 
platelet exocytosis is controlled. Post-translational modifications, such as 
phosphorylation and acylation, have been shown to affect signaling pathways and 
platelet function. In this dissertation, I focus on how these modifications affect the 
t-SNARE proteins, SNAP-23 and syntaxin-11, which are both required for platelet 
secretion. SNAP-23 is regulated by phosphorylation. Using a proteoliposome fusion 
assay, I demonstrate that purified IκB Kinase (IKK) phosphorylated SNAP-23, which 
increased the initial rates of SNARE-mediated liposome fusion. SNAP-23 mutants 
containing phosphomimetics showed enhanced initial fusion rates. These results, 
combined with previous work in vivo, confirm that SNAP-23 phosphorylation is 
involved in regulating membrane fusion, and that IKK-mediated signaling contributes 
to platelet exocytosis.  
 
To address the role(s) of acylation, I sought to determine how syntaxin-11 and 
SNAP-23 are associated with plasma membrane. Using metabolic labeling, I showed 
that both proteins contain thioester-linked acyl groups which turn over in resting cells. 
Mass spectrometry mapping showed that syntaxin-11 is modified on C275, 279, 280, 
282, 283 and 285, while SNAP-23 is modified on C79, 80, 83, 85, and 87. To probe 
the effects of acylation, I measured ADP/ATP release from platelets treated with the 
acyl-transferase inhibitor, cerulenin, or the thioesterase inhibitor, palmostatin B. 
Cerulenin pretreatment inhibited t-SNARE acylation and platelet function while 
palmostatin B had no effect. Interestingly, pretreatment with palmostatin B blocked 
the inhibitory effects of cerulenin suggesting that maintaining the acylation state of 
platelet proteins is important for their function. Thus my work indicates that the 
enzymes controlling protein acylation could be valuable targets for modulating 
platelet exocytosis in vivo. 
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Chapter One: Introduction 
Overview: 
Platelets, as the smallest cells in the blood stream, are anucleate, discs that 
originate from megakaryocytes in bone marrow (1). Their structure is relatively 
simple. They contain granules, a membrane structure called the open canalicular 
system (OCS), microtubules, and mitochondria (2). When a vascular injury occurs, 
platelets use their numerous surface receptors to detect components, released and/or 
exposed, at the site of damage. They act as “first-aid kits” adhering to the injury, 
changing their shapes, and aggregating to form a hemostatic plug. The contents from 
platelet granules are also released upon activation. Cargo, released from platelets, 
control the vascular microenvironment at the injury site. Some cargo is important for 
recruiting other platelets, other cargo affects the surrounding cells. Due to these 
specific effects, it is important to understand what kind of molecules are in the 
granules, and how they are released.  
Proteomic studies have identified hundreds of different molecules in platelet 
releasates (3,4). These components are stored in three distinct types of granules: 
α-granules, dense core granules, and secretory lysosomes. Cargo from α-granules 
contribute to primary and secondary hemostasis as well as to the sequelae of vascular 
injury (5). For instance, adhesive proteins, fibrinogen and von Willebrand Factor 
(VWF), play an important role in mediating platelet-platelet and platelet-endothelial 
interactions. Coagulation factors, such as Factors V, XI, and XIII, are also released 
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from α-granules. Dense core granules contain small molecules (i.e., ADP, serotonin, 
polyphosphate, calcium), which are important for hemostasis (6). ADP is needed to 
recruit and activate more platelets and polyphosphates promote coagulation factor 
production (7). Secretory lysosomes contain a broad range of degradative enzymes, 
and though their precise function has not been established, they are thought to 
contribute to clot remodeling and to further platelet activation (7).  
Platelets are also involved in inflammation and angiogenesis, and thus may 
contribute to cardiovascular disease, asthma, and cancer progression (8,9). Platelets 
release factors whose roles extend beyond initial hemostasis. Proangiogenic factors, 
such as vascular endothelium growth factor (VEGF) as well as antiangiogenic factors 
(angiostatin) have been detected in releasates (10,11). This contribution to 
angiogenesis may accelerate the progression of cancer diseases (12). Platelets also 
release a host of mitogens such as platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), and epidermal growth factor (EGF), which are thought to 
promote wound healing (13). Finally, platelet can release several chemokines and 
cytokines which undoubtedly affect immune responses at the sites of vascular damage 
(14). Given this diversity of releasate components and their potential effects, it is 
critical that we understand how platelet secretion occurs and how it can be controlled.  
Platelets are similar to other secretory cell types that release cargo from different 
classes of granules i.e., mast cells, neutrophils, etc. In platelets, granules appear to 
undergo many of the steps that are thought to control regulated exocytosis, such as 
targeting, tethering, docking, priming. These steps culminate in a granule-plasma 
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membrane fusion event to release cargo. The secretion pathway is mediated by 
sequential protein-protein interactions leading up to the pairing of membrane 
associated SNAREs (soluble N-ethylmaleimide-sensitive fusion protein attachment 
receptors) that span the two bilayers and promote membrane mixing and fusion. 
While many of these SNARE regulators are studied in our laboratory, this dissertation 
focuses on how post-translational modifications, specifically of the t-SNAREs, affects 
their roles in granule secretion.  
Platelet Structure 
Platelets are produced from megakaryocytes, and released into circulation 
(15,16). Their life span is around 7-10 days in human (3-5 days in mice). Because of 
their discoid shape and small size, platelets are carried along by the blood flow and 
pushed to the perimeter of the vessels, where they are better able to detect vascular 
lesions (1). In a resting platelet, its discoid shape is maintained by cytoskeleton, 
consisting of actin and tubulin. With observation from electron microscope (EM) 
images, the polymers of actin interconnect with spectrin strands, and form the 
spectrin-based membrane skeleton adjacent to cytoplasmic side of plasma membrane 
(17,18). In addition, actin filaments form a rigid network, which crosslinks with 
filamin and α-actinin (19). Filamin, as a scaffolding protein, can bind to GTPases, 
kinases, phosphatase and transmembrane proteins and localize them to plasma 
membrane in platelets (20). Also, each platelet contains one single microtubule, a 
polymer of αβ tubulin dimers, which forms a circumferential coil that is disassembled 
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upon platelet activation (21). In the surface of platelet disc, there are invaginations on 
plasma membrane, called the open canalicular system (OCS). OCS is a reservoir of 
membrane for activation-induced platelet spreading (22). The OCS, an invaginated 
tubular membrane region in platelets, is thought as site for granule fusion and as a 
membrane reservoir (23).  
There are three distinct types of granules in platelets: dense core granules, 
α-granules, and secretory lysosomes. There are around 50-80 α-granules in per 
platelet and their size ranges from 200 to 500 nm (24). As the largest and the most 
abundant, α-granules contain the most diverse array of secretory molecules, such as, 
growth factors, adhesive receptors, and glycoprotein receptors. Some of the proteins 
are produced in megakaryocytes cells, such as platelet-specific proteins, platelet factor 
IV (PF4) and β thromboglobulin (5). α-granules can be identified by electron 
microscopy and immunofluorescence microscopy (5,25). Several established specific 
α-granule markers, such as P-selectin, vWF, PF4, and fibrinogen are used to identify 
α-granules. In this dissertation, PF4 was used as the α-granule marker in certain 
assays. P-selectin, on the luminal side of α-granule membranes, is exposed on the 
platelet surface and can be used as a marker to assay α-granule exocytosis by FACS. 
Many of the proteins discussed are synthesized de novo in the megakaryocyte; 
however, there are a number of proteins that are taken up by platelets and stored in 
α-granules. For instance, fibrinogen (Fg) is produce by the liver and taken up into 
α-granule (26). Interestingly, this platelet pool of Fg accounts for approximately 3% 
of the total circulating Fg. The second most abundant secretory granules are the dense 
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granules. These granules have smaller size and number (~7 per platelet) and they 
contain ADP, ATP, GDP, serotonin, Ca
2+
, Mg
2+
 and other divalent cations (24). ADP 
and serotonin are activators in the “second wave” of platelet aggregation and are 
amplifiers of platelet activation. In the dissertation, ATP was used as a marker for 
dense core granule secretion. The secretory lysosomes represent the least abundant 
granules with about 5 per platelet. These granules contain membrane proteins such as 
LAMP-1, 2, and 3. Hydrolases, β-hexosaminidase, cathepsin, and acid phosphatases 
are also present in lysosomal granules (27). These enzymes are released only when 
platelets are stimulated with strong agonists (28). Overall, there are several hundred of 
molecules secreted from platelets, which affect vascular microenvironment. Platelets 
are involved in thrombosis, angiogenesis, inflammatory disease and cancer 
progression. So, it is essential to understand how to control platelet secretion.  
SNARE Machinery in Platelets  
Platelet granule secretion is the process mediated by protein-protein interactions. 
The targeting granules tether and dock to plasma membrane, where they fuse. Upon 
activation, intracellular [Ca
2+
] increases and the secretory granules fuse with plasma 
membrane. This mediates the rapid release of granule cargo. At the same time, 
granule membranes fully fused to become part of the plasma membrane. SNARE 
proteins mediate these membrane fusion steps. SNARE proteins were initially 
described by Söllner et al.(29), who proposed that SNARE proteins are important for 
vesicle fusion in neurotransmitter release. There are numerous SNARE proteins 
identified in many species and this diversity suggests that specific SNAREs may be 
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responsible for distinct vesicles. In secretory cells, e.g. neurons, mast cells, and 
platelets, exocytosis is mediated by SNARE proteins residing on target membrane 
(t-SNAREs) and on vesicles/granules (v-SNAREs). t-SNAREs and v-SNAREs form a 
trans-bilayer, four-helix bundle of coiled-coil domains which is needed for membrane 
fusion (30).  
In neuronal cells, syntaxin-1, SNAP-25 and VAMP-2 are the primary SNARE for 
synaptic release, and these three proteins form a four-helix bundle (2 helices from 
SNAP-25 and 1 each from VAMP-2 and syntaxin-1) (31). Weber et al. showed that 
fusion occurs when t-SNARE- and v-SNARE-containing proteoliposomes were 
mixed in vitro. These data showed that the SNAREs are the minimal element required 
for membrane fusion (32). The SNARE complex (VAMP-2, syntaxin-1 and SNAP-25) 
were shown to be SDS-resistant in vitro and in living cells, suggesting that once 
formed, it is very stable (33,34). The SNARE complexes may also contribute to other 
steps in the process, such as tethering or docking of vesicles to target membranes 
(30,35).  
There are numerous SNAREs identified in platelets. t-SNARE isoforms include 
syntaxin-2, -4, -6, -7, -8, -11, -16, -17, -18, SNAP-23, SNAP-25 and SNAP-29; 
v-SNARE isoforms include VAMP-2, -3, -4, -5, -7 and -8 (36-38). Among those 
SNAREs, VAMP-8, syntaxin-11 and SNAP-23 are identified as primary SNAREs, 
which are required for membrane fusion in platelets. Analysis of syntaxin-2 and -4
 
double knockout mice showed that loss of syntaxin-2 and -4 does not affect platelet 
secretion. Syntaxin-11 has been shown to be required for platelet secretion in three 
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classes of granule secretion (39). As one of the primary t-SNAREs, syntaxin-11 is 
first reported as an atypical t-SNARE because it lacked a typical transmembrane 
domain and instead had a C-terminal cysteine-rich region (40). Syntaxin-11 is 
expressed in various tissues, but is enriched in cells from the immune system (41). It 
has been found on endosomes and was reported to participate in regulating late 
endosome to lysosome fusion in macrophages (42). Syntaxin-11, like syntaxin-2, -3, 
and -4, is also found on the plasma membrane in polarized Madin-Darby canine 
kidney (MDCK) cells (43). Although syntaxin-11 does not contain transmembrane 
domain (TMD) (40), it behaves as integral membrane protein (44). Syntaxin-11 
mutations were identified in familial hemophagocytic lymphohistiocytosis 4 (FHL4) 
patients (45), and syntaxin-11 is required for NK cell, CD8
+
 T-cell degranulation and 
platelet secretion (46). Munc18-2 is syntaxin-11 chaperone and mutations in 
Munc18-2 disrupt its binding to syntaxin-11 resulting in decrease levels of 
syntaxin-11 (47). Ye et al.showed that syntaxin-11, but not syntaxin-2, or -4 is 
required for platelet secretion (39). In recent study, syntaxin-8 has been found to form 
complexes with syntaxin-11 in platelets and to be specifically important for dense 
core granule secretion and platelet aggregation but not essential for α- and lysosomal 
granule secretion (48). 
The t-SNARE SNAP-23 is widely expressed in many tissues and and is highly 
expressed in platelets. Its homologues, SNAP-25 and SNAP-29 are expressed at much 
lower levels (37,38). SNAP-23 is widely believed to play a key role in exocytosis in 
most cells that do not express SNAP-25 (49). Due to its ubiquity, SNAP-23 deficiency 
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causes implantation embryonic lethality in mice (49). Anti-SNAP-23 antibody can 
inhibit granule docking to target membranes (50). SNAP-23 is important for 
exocytosis of platelet α-granules (51), dense granules (50) and lysosomal granules 
(52). SNAP-29 null platelets did not have secretion defect (53). 
Platelet secretion is attenuated, but not ablated in VAMP-8
-/-
 mice. VAMP-3
-/-
, 
VAMP-2
+/-
 and VAMP-2/3
-/-
 platelets did not show significant secretion defects (54). 
These data suggested that VAMP-8 is the primary v-SNARE. Treatment of 
permeabilized VAMP-8
-/-
 platelets with a VAMP-2/3 cleaving toxin ablated secretion, 
suggesting a secondary role for VAMP-2 and/or -3 (54). In our lab’s recent studies, we 
showed that secretion of the three types of granule can be greatly decreased 
VAMP-2/3/8
-/-
 platelets, further indicating that VAMP-2, -3, -8 (VAMP-8 as primary; 
-2, -3 as secondary) co-regulate platelet secretion in mouse platelets (Smita Joshi 
unpublished data). Consistently, there does appear to be a role for VAMP-7 in platelet 
exocytosis. Flaumenhaft and colleagues reported a partial dense core granule and 
α-granule secretion defect in VAMP-7
-/-
 platelets (55). Taking all of these data into 
account, it would seem that VAMP-8 mediates to highest level of platelet secretion 
followed by VAMP-7 and that VAMP-2 or -3 can serve as compensatory VAMPs 
when neither VAMP-7 nor -8 is present. 
SNARE Regulators in Platelets 
While SNAREs alone are sufficient for membrane fusion (32), fusion is 
Ca
2+
-independent and slow (min-hr) in vitro. In vivo, granule release is not only 
Ca
2+
-dependent but also fast. It takes milliseconds for neurotransmitter release and 
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seconds for platelet exocytosis (56-58). SNARE proteins are core elements for 
membrane fusion. In secretory cells, regulators control both the temporal and spatial 
aspects of cargo release. Similar to neurotransmitter release, several SNARE effectors 
are Ca
2+
 sensors. Some are present in platelets. Munc13-4, Munc18-2, 
STXBP5/Tomosyn-1, as SNARE effectors, have received much attention because 
they interact with syntaxins (59-62). Deficiency in SNARE-regulators results in 
defective granule secretion (63,64). 
Munc13-4 
Munc13s contain two C2 (C2A and C2B) domains. Munc13s are thought to be 
priming factors in granule secretion. There are four isoforms detected in mammals: 
Munc13-1, Munc13-2, Munc13-3, and Munc13-4. Munc13-1, -2, -3 are exclusively 
expressed in brain. In a Munc13-1/2
-/-
 mouse model, release from glutamatergic and 
from GABAergic neurons are completely blocked, indicating that Munc13-1 and 
Munc13-2 are required for neurotransmitter release. Mechanistically, Munc13-1 is 
thought to regulate neuronal secretion by promoting the transition of syntaxin-1 from 
its closed conformation to an open conformation that can form trans-SNARE 
complexes (65). Another homologue, Munc13-4 has been identified and is widely 
expressed in non-neuron tissues. Munc13-4 is a Rab 27-binding partner which 
participates in regulating Ca
2+
 triggered dense core granule secretion in platelets 
(66-68). Mutations in Munc13-4 are related to a fatal hyperinflammatory disorder 
called Familial Hemophagocytic Lymphohistiocytosis type 3 (FHL3). In the 
Munc13-4
-/-
 mouse model, dense core granule secretion is abolished, and α- and 
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lysosomal granule secretions are attenuated (69). Munc13-4 contains two C2 domains 
(C2A and C2B) which are Ca
2+ 
binding sites. In vitro fusion assays show that 
Munc13-4 regulates membrane fusion in Ca
2+
- and phosphatidylserine 
(PS)-dependent manner and may span the two fusion bilayers to promote SNARE 
complex formation. (70).  
Munc18-2 
There are three isoforms in the Munc18 family, Munc18-1, -2, and -3, which are 
all expressed in platelets (71). Munc18-1 is mostly expressed in neuronal tissue and 
binds to syntaxin-1 and regulates SNARE complex assembly. Because Munc18-3 
deficient mice did not survive past birth, platelets from Munc18-3
+/-
 mice were used 
for granule secretion studies. There was no secretion defect detected (72). In Familial 
Hemophagocytic Lymphohistiocytosis type 5 (FHL5) patients, Munc18-2 is deficient. 
This causes a granule secretion defect in platelets, indicating that Munc18-2 is 
required for granule secretion in platelets (73,74) . Consistently, the expression of 
syntaxin-11 was also affected by the loss of Munc18-2. 
Other Regulators 
Rab27s is a member of the Rab family of small GTPases. Two isoforms, Rab27a 
and Rab27b have been detected in platelets. In a recent study, using a Rab27ab
-/-
 
mouse, Rab27s were shown to be required for dense core granule biogenesis and 
granule secretion, but not in α-granules and lysosomes, indicating Rab27s is important 
for granule packaging and secretion(75) 
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STXBP5/Tomosyn-1 was originally identified in rat brain as a syntaxin-1 
binding protein, hence the name syntaxin binding protein 5 also called “friend of 
Syntaxin” or tomosyn (STXBP5//Tomosyn-1). All the isoforms of Tomosyn-1 (b-, m-, 
s-) contain a C-terminal of v-SNARE motif, suggesting that it helps form SNARE 
complex with syntaxin-1 and SNAP-25 (76). Tomosyn-1 is thought as a negative 
regulator of neuron transmitter release and vWF release from endothelial cells and 
this has been borne out in studies of knockout mice (77); however, it is a positive 
regulator that is required for granule secretion in platelets (78). Mice, deficient in the 
platelet STXBP5//Tomosyn-1 showed an enhanced bleeding diathesis, despite higher 
than normal levels of circulating vWF. 
SNARE Phosphorylation 
In addition to those regulators in platelets, post-translational modifications are 
ubiquitous in secretory cells and have been shown to be important for granule 
exocytosis. Phosphorylation is a post-translational modification and may affect 
protein-protein interaction, affinity of protein complex. Protein kinase C (PKC) was 
identified as one of the major kinases regulating protein phosphorylation. In response 
to phorbol ester, SNAP-25 phosphorylation was detected in many cell types, e.g., 
PC12 cells, pancreatic β cells and chromaffin cells. Ser187 is one of the identified 
phosphorylation sites. PKA and casein kinase II (CKII) both can phosphorylate 
SNAP-25 in vitro. Interaction with SNAP-25 are disrupted when SNAP-25 was 
phosphorylated by PKA, but not CKII (79), indicating that SNAP-25 phosphorylation 
affects SNARE complex affinity. IĸB Kinase beta (IKKβ) directly phosphorylates 
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SNAP-23 at Ser95 and Ser120 in mast cells and in activated platelets. In another study, 
purified PKC can also phosphorylate SNAP-23, but not at Ser95 or Ser120. Based on 
data from our laboratory, it seems that IKKβ may be a downstream effector of PKC in 
activated platelets, since PKC inhibitors affect IKK activation but IKK inhibitors have 
no effect on PKC activation (80).  
Another t-SNARE protein, syntaxin-4 is also phosphorylated in 
thrombin-activated human platelets, and its phosphorylation can be inhibited by PKC 
inhibitor (81). Munc18-1 is phosphorylated in response to phorbol ester treatment in 
adrenal chromaffin cells, and purified PKC can phosphorylate Munc18-1 at Ser313 in 
vitro (82). Phosphorylation of Munc18-1 by PKC reduced the binding affinity to 
syntaxin-1 in binding assay (82). Above all, it is indicated that Munc18-1 
phosphorylation is important for granule secretion by PKC. 
Phosphorylation of SNAP-23: 
Phosphorylation of other SNAP-23 superfamily members has been detected. 
SNAP-25 is phosphorylated by PKC in vitro (83,84). SNAP-25 has been shown to be 
a PKC substrate in some cell types e.g., PC12 cells (85,86), hippocampal organotypic 
cultures (87), pancreatic β cells (88) and adrenal chromaffin cells (89). 
Phosphorylation of SNAP-23 promotes its association with other SNAREs in the 
process of SNARE complex formation in mast cells (90). Phosphorylation of 
SNAP-23 enhances t-SNARE complex assembly by SNAK (SNARE kinase) (91). In 
activated mast cells and platelets, Ser95 and Ser120 are phosphorylated (83). In 
Figure 1-1, Ser95 and Ser120 are close to the cysteine-rich region between N- and C- 
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terminal coiled-coil domains. Upon activation, SNAP-23 phosphorylation appears to 
promote SNARE complex formation (syntaxin-11/SNAP-23/VAMP-8 and 
syntaxin-2/SNAP-23/VAMP-8). Consistently, SNARE complexes could not be 
detected in co-immunoprecipitation assay and SNAP-23 phosphorylation was also 
affected in IKKβ
-/- 
platelet lysate (80). To understand the importance of 
phosphorylation in SNAP-23, it is critical to identify which kinase is responsible for 
SNAP-23 phosphorylation.  
IKK Complex and its Inhibitors 
The IKK complex is composed of catalytic and regulatory subunits. The catalytic 
subunits, IKKα and IKKβ, are regulated by IKKγ (92-95). All elements of IKK 
complex are present in platelets (80). Normally, IKK regulates NF-κB signaling 
pathway and thus several IKK inhibitors have been created to modulate inflammation 
and cell growth in cancer cells [32-34]. IKKβ inhibitors, such as BMS 345541, BAY 
11-7082, and TPCA-1, have been used in preclinical trials as anti-cancer and 
anti-inflammatory agents (96-98). SNAP-23 is phosphorylated by IKKβ in mast cells 
(99). Recently, it was reported that IKK phosphorylates Ser95 and Ser120 of 
monomeric SNAP-23 as well as in SNARE complex in activated mast cells (83,99). 
This appear to promote SNAP-23 association with syntaxin-4 and VAMP-8 in lipid 
rafts (99). Phosphorylation of SNAP-23-IKK complexes was detected in 
lipopolysaccharide (LPS)-activated bone marrow–derived mast cells (100). IKKβ
-/-
 
platelets and inhibitor-treated platelets displayed decreased SNAP-23 phosphorylation, 
diminished SNARE complex formation, and decreased granule secretion (80) . Mice 
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treated with IKKβ inhibitors showed a significant increase in tail-bleeding time. These 
data show that IKKβ can phosphorylate SNAP-23 at Ser95 in platelets, which is 
important for platelet secretion. Both Ser95 and Ser120 are adjacent to the 
cysteine-rich region involved in anchoring SNAP-23 to membranes via its acylation 
(Figure 1-1) (101). It is unknown whether the phosphorylation of Ser95 and/or Ser120 
is involved in regulation of SNARE complex assembly, selectivity, or membrane 
fusion. The role of phopho-Ser95
 
in regulating SNARE complex formation and 
membrane fusion remains uncharacterized. In the dissertation (Chapter 3), I will use 
in vitro fusion assay and mutagenesis to address some of these questions.  
Acylation and Deacylation 
In addition to phosphorylation, there are forms of post-translational modification 
(PTM), which are essential for protein function in platelets. Acylation has been 
identified in platelets, which is thought to be important in the regulation of platelet 
function (102,103). It is one of the PTM ubiquitously found in all eukaryotes. 
Unsaturated fatty acid, palmitate (C16) reversibly forms lipid anchors for several target 
proteins via thioester bonds (S-palmitoylation) and irreversibly through amide bonds 
(N-palmitoylation). N-palmitoylation occurs at N-terminal cysteines or glycines and is 
especially found in secreted proteins (104). Due to the amide bonds, N-palmitoylation 
is an irreversible modification, similar to prenylation and myristoylation. As opposed 
to other PTMs, S-palmitoylation is readily reversible PTM and does not require any 
specific sequence motif. C16 covalently attaches to cysteine residues of proteins via a 
thioester bond. Different lengths of fatty acids, such as C18 (called stearate (18:0), C20 
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(called arachidonate (20:4), attach to cysteine residues, are generally called 
S-acylation; however, S-palmitoylation is the most common among S-acylation.  
S-acylation can affect its target protein’s characteristic, and change its function, 
causing the effects in various events of the cells. Firstly, acylation, as one of the 
common PTMs, serves as membrane anchors, and also localizes the proteins into lipid 
rafts. Fatty acids covalently attached to proteins increase their hydrophobicity, and 
thus serve as membrane anchors especially for those proteins lacking TMD. For 
instance, SNAP-25, in neuronal and neuroendocrine cells, contains a cysteine-rich 
region, which is palmitoylated and mediates attachment of the t-SNARE to plasma 
membrane (105). For those proteins containing TMD, acylation may help proteins 
associate with the plasma membrane or redistribute to intracellular compartments, 
such as lipid rafts. Beyond that, acylation also plays an important role in cell signaling, 
protein localization, protein stability, and protein-protein interactions (106-109).  
There are several hundred S-palmitoylated proteins in mammals (110,111). 
Dowal et al. analyzed palmitoylated proteins by proteomic approaches and revealed 
that ~215 proteins among ~1500 proteins are palmitoylated in platelets (112). Those 
215 known or novel candidate, palmitoylated proteins have diverse functions such as: 
cell signaling, immune response, cell growth, apoptosis, metabolism, transport, 
protein folding, DNA repair. This suggests that acylation may play multiple roles in 
platelets.  
Acylation of SNAREs  
SNAREs acylation has been detected in diverse cells or tissues, such as neurons, 
neuroendocrine, mast cells and platelets. Platelet palmitoylation studies from Dowal 
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et al. showed that numerous SNAREs are acylated. SNAP-23, syntaxin-2, -8, -10, -11, 
-12 and VAMP-3, -4, -5, -7 were identified as known or novel candidates in platelet 
“palmitoylome” (112). 
SNAP-25 is well-known acylated proteins, and its 4 cysteines in the linker region 
connecting the two α-helices domains can be all modified. In metabolic labelling 
experiment, [
3
H] palmitic acid incorporated into SNAP-25 in CV-1 kidney cells, all 
the 4 cysteines can be palmitoylated (113). Acylation also appears to regulate 
intracellular trafficking and exocytic function of SNAP-25 (114). Besides SNAP-25, 
synaptic SNARE proteins, VAMP-2 (115) and syntaxin-1 (116), together with 
synaptotagmin I (113) in neurons were also reported, indicating that palmitoylation is 
important for SNARE protein-mediated membrane fusion in synaptic vesicle fusion. 
The primary platelet t-SNAREs, SNAP-23 and syntaxin-11, lack TMDs and 
contain cysteine- rich regions (Figure 1-2). As the homologue of SNAP-25, SNAP-23 
is also palmitoylated in HeLa cells (101) and platelets (112). SNAP-23 and its 
homologue SNAP-25 are thought to be associated with membranes by acylation 
and/or by association with syntaxin isoforms (117,118). There is a cysteine-rich 
region in the linker region between N- and C- terminus of SNAP-23 (Figure 1-2B), 
demonstrating that acylation of cysteine residues may change the hydrophobicity of 
SNAP-23 and thus cause it to behave like integral membrane proteins (119). 
SNAP-23 contains 5 cysteines in cysteine-rich region and one more cysteine 
compared with SNAP-25, and additionally, more SNAP-23 enriched into lipid rafts in 
PC12 cells. A single mutation of cysteines in SNAP-23 (similar to SNAP-25) causes 
the level of SNAP-23 associated with lipid rafts to drop to a level similar to that of 
SNAP-25, implying that cysteine number affect SNAP-23 distribution and association 
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in the plasma membrane (120) . Alternatively, acylation sites may affect membrane 
association, even lipid rafts association.  
Although syntaxin-11 lacks TMD (Figure 1-2A), it behaves like an integral 
membrane protein in NK cells, HeLa cells and platelets (39,44). It is also shown that 
syntaxin-11 is acylated in natural killer cells and syntaxin-11 disassociated with 
plasma membrane when 5 cysteine residues were replaced with Ala at C-terminus 
(121). When C-terminus of syntaxin-11 was deleted, truncated syntaxin-11 in HeLa 
was still partially associated with membrane by immunofluorescence microscopy, 
indicating that the C-terminus are not determining factor for its membrane association 
in HeLa cells (44).  
However, it is still unclear how acylation of t-SNAREs affect their localization 
and function of the proteins in platelets, and how acylation happens to t-SNARE 
membrane association and whether it can affect granule secretion in platelets or not. 
With those questions, biochemical assays and ex vivo experiments were performed to 
provide clues in the dissertation (Chapter 4). 
Enzymes for Acylation Regulation 
There are several hundred of acylated proteins identified in platelets. Where are 
the fatty acids coming from? The resource of palmitate is from palmityl-CoA at 
nanomolar concentrations (122); however, the cycle of acylation and deacylation of 
proteins changes dynamically. The localization of H-Ras and N-Ras can be regulated 
rapidly through reacylation/deacylation cycle. The half-life of N-Ras acylation is less 
than 20 min (123-126). How could the cycle be regulated rapidly within such low 
concentration of palmityl-CoA in physiological contexts? S-acylation is enzymatically 
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regulated by opposing activities of two families of enzymes: protein acyltransferases 
(PATs) and Acyl Protein Thioesterases (APTs). S-acylation is a reversible process via 
a thioester bond. The major role of PAT is to enzymatically attach palmitate to 
specific cysteine residues. Conversely, APTs catalyze the reaction to remove acyl 
group and thus depalmitoylate proteins. There are only four identified APTs in 
mammalian cells in Table 1-1: acyl protein thioesterase 1 (APT1), acyl protein 
thioesterase 2 (APT2), palmitoyl protein thioesterase 1 (PPT1), and palmitoyl protein 
thioesterase 2 (PPT2) (102,127). PPT1 and PPT2 were found in lysosomes and play 
an important role in degradation of palmitoylated proteins (128). 
Syntaxin-2/SNAP-23 complex can be released from platelets when treated with APT1 
(specifically removing palmitate) and botulinum toxin C (specifically cleaving 
syntaxin isoform), indicating that APT1 also can regulate depalmitoylation of 
SNAP-23(129). APT2 is 68% homologous to APT1, but can specially depalmitoylate 
the axonal GAP43 (130).  
Typical PAT contains a cysteine-rich domain and a conserved Asp-His-His-Cys 
(DHHC) motif (131-133). There are 24 genes encoding proteins called ZDHHC in 
mammals and 25 in human (134,135). PAT activities highly depend on DHHC 
domain, since mutations of the cysteine of DHHC abolish the activity of acylation and 
self-palmitoylation in ZDHHC proteins (136). The majority of PATs also contain two 
other conserved motifs, DPG (aspartate-proline-glycine) motif and TTxE 
(threonine-threonine-asparagine-glutamate) motif, and so far, little is known about 
their function (137) . Most of the PATs were detected in ER or Golgi; however, some 
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localized to plasma membrane (138). It is demonstrated that neural PATs exhibit 
distinct substrate specificity (139). For instance, HIP14 (ZDHHC17) enhances 
palmitoylation of SNAP-25 in neuronal cells (131,140). ZDHHC2 also palmitoylates 
SNAP-25 in PC12 cells (141). Nine ZDHHC genes related to PATs are identified and 
associated with human disease: Huntington Disease (HIP14/ZDHHC17) (142-144), 
Schizophrenia (ZDHHC8) (145), Alzheimer Disease (ZDHHC12) (146), Mental 
retardation (ZDHHC9/15) (147), and cancers (ZDHHC2/9/11) (148-151). So far, 
there are at least 13 ZDHHC proteins or their mRNAs detected in platelets (Table 
1-1).  
Overall, due to the reversibility of S-acylation, it can be regulated by opposing 
action of enzymes, PATs and APTs. In previous study, PATs harbor the specificity 
for acylating certain proteins and APTs are less specific, There are almost certainly 
more APTs unidentified. In the dissertation, there are some function studies to address 
the importance of acylation in platelet secretion. PAT and APT inhibitors were used 
in these studies.  
Inhibitors of PATs and APTs 
2-bromopalmitate (2BP) and cerulenin (2,3 epoxy-4-oxo-7,10 dodecadienamide) 
are widely used for regulating PAT enzyme activity (Figure 1-3) (154-156). Cerulenin 
is a natural and lipid-based inhibitor of fatty acid synthesis and protein palmitoylation 
(157). It can irreversibly alkylate cysteines in PATs to prevent acyl-enzyme adduct 
formation (158). Also, cerulenin, as an acylation inhibitor in platelets, inhibits platelet 
aggregation and thrombus formation in vivo (102). 2BP has been more commonly 
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used as an acylation inhibitor (132,159-161). This palmitate analog has been used in 
platelets and it inhibited acylation of CD63 and CD9, affecting the 
tetraspanin-tetraspanin interaction (159). In acylation studies, 2BP and cerulenin were 
used to treat washed platelets. One of drawbacks of PATs inhibitors is that 2BP and 
cerulenin are nonselective probes among the PATs.  
Unlike the large numbers of PATs, only four APTs have been identified in the 
cells, which contain thioesterase signatures: both the S-H-D catalytic triad and a 
G-X-S-X-G motif. Increasing evidences show that only two cytosolic APT1 and 
APT2 are the major APTs responsible for deacylation in diverse substrates (162-164). 
For APT inhibitors, Palmostatin B is an inhibitor of β-lactone acyl protein thioesterase 
1 as shown in Figure 1-4. In the presence of Palmostatin B, the proper localization of 
H-Ras and N-Ras was disrupted, and therefore the signaling pathway was 
down-regulated (165). Although Palmostatin B is a selective inhibitor for APTs, both 
isoforms, APT1 (IC50=5.4 nM) and APT2 (IC50=37.7 nM) are inhibited by 
Palmostatin B (166). Palmostatin B is used to study acylation of t-SNARE in my 
dissertation. Palmostatin M ((APT1 (IC50=2.5 nM) and APT2 (IC50=19.6 nM)), a 
more potent and more soluble analog, was further developed and tested as a 
deacylation inhibitor (167); however, it is not commercially available and could not 
be used for my studies. Both Palmostatin B and M are non-selective for APT1/2 
isoforms as indicated by their IC50. 
Lipid Rafts in Platelets 
Often, acylated proteins lacking a TMD, gain the ability to move around plasma 
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membrane, especially to lipid rafts (168). Lipid rafts are island-like subdomains of the 
plasma membrane, consisting of cholesterol, glycosphingolipids and raft-associated 
proteins (169). The lipid rafts can be regulated dynamically by cell signal pathway 
and palmitoylated proteins reside in the specific domain participate cell signaling 
events and protein complex formation. Acylated proteins have an affinity for lipid 
rafts; however, prenylated proteins have little affinity for lipid rafts (170), indicating 
that distribution of acylated proteins may change as raft changes its localization. For 
t-SNARE proteins in platelets, acylation as a lipid anchor may enhance proteins 
hydrophobicity. Syntaxin-11 and SNAP-23 redistribute into lipid rafts upon activation 
in platelets and also in mast cells (80,90). But it is unclear whether acylation will be 
one important factor for protein redistribution in lipid rafts or not. In the dissertation, 
lipid rafts were isolated for detecting t-SNARE redistribution upon platelet activation. 
Dissertation Overview 
Abnormal platelet function can cause bleeding or spurious thrombosis leading to 
strokes and heart attacks. Given its importance, it is critical to understand how platelet 
exocytosis is controlled. From previous study, it is believed that SNAREs form a 
four-helix bundle, and then mediate membrane fusion in platelets. Regulatory proteins, 
such as Munc13-4, Munc18-2, Tomosyn-1 and Rab 27, play an important role in 
regulation platelet granule secretion. At the same time, posttranslational modifications, 
such as phosphorylation and acylation, have been shown to affect signaling pathways 
and platelet function.  
First, to identify the effect of phosphorylation in membrane fusion (in Chapter 3), 
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using an in vitro, proteoliposome fusion assay, we demonstrated that purified IκB 
Kinase (IKK) phosphorylates SNAP-23 and this increases the initial rates of 
SNARE-mediated liposome fusion. Both phosphorylation and fusion enhancement 
were blocked by the addition of the IKK inhibitors, BMS 345541 and TPCA-1. 
Phosphomimetic study showed that phosphomimetic group in Ser95 enhanced 
membrane fusion in proteoliposome fusion assay. These results, combined with 
previous work in vivo, suggest that SNAP-23 phosphorylation at Serine 95 is involved 
in regulating membrane fusion, and that IKK-mediated signaling contributes to 
platelet exocytosis.  
As t-SNARE proteins, SNAP-23 and syntaxin-11, lack TMD, but are required for 
platelet secretion. Both of the t-SNAREs contain cysteine-rich region as putative 
acylation sites. Little is known about how SNAP-23 and syntaxin-11 behave as 
integral membrane proteins and whether acylation can affect SNARE mediated 
membrane fusion or not.  
To answer these questions, biochemical and cell biological assays were 
performed in the first part (Chapter 4) of the dissertation. In the subcellular 
fractionation assays, syntaxin-11 and SNAP-23 are membrane associated proteins and 
redistributed into lipid rafts together with v-SNARE protein, VAMP-8, indicating that 
lipid rafts are the sites for membrane fusion. Using IP-ABE assays, we showed that 
both syntaxin-11 and SNAP-23 are modified by thioester-linked palmitic acid in 
platelets. To map the sites of acylation, syntaxin-11 and SNAP-23 were purified from 
platelets and analyzed by mass spectrometry. Our results showed that each cysteine in 
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cysteine-rich region can be acylated in syntaxin-11 and SNAP-23. [
3
H]-palmitic acid 
metabolic labeling reveals that acylation of syntaxin-11 and SNAP-23 are dynamic, 
and turns over in resting platelets without affecting t-SNARE protein synthesis. To 
understand the potential role of changing acylation patterns, total acylation, 
aggregation, and ADP/ATP release were measured in platelets treated with an 
acyltransferase inhibitor, cerulenin, and/or acyl-protein thioesterase inhibitor, 
palmostatin B. Our data suggest that t-SNARE acylation turns over in resting platelets 
and that this cycling could be important for exocytosis. Overall, acylation of 
t-SNARE are dynamic and also can be regulated by APT and PAT inhibitors, and most 
importantly, acylation can affect SNARE mediated fusion in platelets. 
In summary, SNARE protein modifications, e.g. SNAP-23 phosphorylation and 
SNAP-23/syntaxin-11 acylation, play key regulatory roles in platelet membrane 
fusion. The work in this dissertation points to two potential post-translation 
modifications that affect platelet t-SNARE function: acylation and phosphorylation. 
We have shown that targeting the enzyme responsible for these modifications can 
affect platelet function ex vivo and thus could be potential drug targets for controlling 
platelet exocytosis in vivo.   
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Figure 1-1 A Cartoon of SNAP-23, Highlighting Ser95 and Ser120 
 
In emphasis on the importance of Ser95 and Ser120 phosphorylation, a cartoon of 
SNAP-23 highlighting Ser95 and Ser120, which locate close to the linker region, 
cysteine-rich residues, of N- and C-terminal coiled-coil regions. Acylation sites are 
indicated in the cysteine-rich residues of SNAP-23.  
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Figure 1-2 Schematic Diagrams of the Predicted Protein Domain Structures of 
Syntaxin-11 and SNAP-23 
Predicted protein domain structures of syntaxin-11 (A) and SNAP-23 (B) based on the 
cDNA sequence from human syntaxin-11 and SNAP-23. A. The cysteine-rich region 
at C-terminus of human syntaxin-11 represents the acylation sites. There are two 
additional cysteines in helical bundle domain. B. There are highly conserved 
coiled-coil domains in human SNAP-23. Cysteine-rich region between coiled-coil 
domains represents the acylation sites. 
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Cerulenin 
 
2-bromopalmitate (2BP) 
Figure 1-3 Lipid-based Inhibitors of Acylation Applied in the Dissertation 
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Palmostatin B 
 
Palmostatin M 
Figure 1-4 Acyl Protein Thioesterae Inhibitors 
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Table 1-1 Palmitoyltransferases and Acyl-Protein Thioesterases Present in 
Platelets 
Name Protein in platelets mRNA Function 
ZDHHC3 Yes(102)  S-palmitoyltransferase activity  
ZDHHC17 Yes(102)  S-palmitoyltransferase activity 
ZDHHC20 Yes(36) and (152) Yes(153) S-palmitoyltransferase activity 
ZDHHC12  Yes S-palmitoyltransferase activity 
ZDHHC16  Yes S-palmitoyltransferase activity  
ZDHHC18  Yes S-palmitoyltransferase activity 
ZDHHC2  Yes S-palmitoyltransferase activity 
ZDHHC21  Yes S-palmitoyltransferase activity 
ZDHHC24  Yes S-palmitoyltransferase activity 
ZDHHC4  Yes S-palmitoyltransferase activity 
ZDHHC5 Yes (36,152) Yes S-palmitoyltransferase activity 
ZDHHC7  Yes S-palmitoyltransferase activity 
ZDHHC8  Yes S-palmitoyltransferase activity 
APT1 Yes (102) (152) 
(127)  
 Hydrolyzes fatty acid 
APT2 Yes (127)  Hydrolyzes fatty acid  
PPT1;  Yes Removes palmitate  
PPT2  Yes Removes palmitate  
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Chapter Two: Materials and Methods 
Materials  
Antibodies: Anti-syntaxin-11 rabbit polyclonal antibody (110113) was from 
Synaptic System GmbH (Gottingen, Germany). Anti-syntaxin-2, -4, and SNAP-23 
polyclonal antibodies were generated in the Whiteheart laboratory as described 
previously (50,52). Anti-Munc18b antibody (sc-14563) was purchased from Santa 
Cruz Inc. (Santa Cruz, CA). Polyclonal rabbit-anti-human VAMP-8 antibody was 
generated in the Whiteheart laboratory using the cytoplasmic domain of human 
VAMP-8 (1-73 aa) as antigen; Anti-RabGDI polyclonal antibody was also generated 
in the Whiteheart laboratory by Dr. Tara Rutledge using recombinant RabGDIα as 
antigen. Fluorescein isothiocyanate (FITC)-conjugated CD62P (recognizes P-selectin 
was from BD Biosciences (San Jose, CA). Alkaline phosphatase conjugated 
secondary anti-murine, anti-rabbit, anti-sheep, and anti-goat IgGs were purchased 
from Sigma. Horseradish peroxidase (HRP) conjugated anti-rabbit IgG was from 
Sigma. HRP conjugated streptavidin was purchased from R&D systems.  
General Reagents: Acid citrate dextrose (ACD) blood collection tubes (364606, 
BD Vacutainer®) were purchased from BD Diagnostics (Sparks, MD). Apyrase, 
cerulenin, diethylamine NONOate diethylammonium salt, urea and N-Ethylmaleimide 
(NEM) were purchased from Sigma (St Louis, MO). HisProbe
TM
-HRP, BCA
TM
 
Protein Assay Kit, EZ-link®BMCC-biotin (1-Biotinamido-4-[4-(maleimidomethyl) 
cyclohexanecarboxamido] butane), hydroxylamine•HCl, iodoacetamide (IAA), 
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Pierce® streptavidin magnetic beads, and Pierce® ECL plus western blotting 
substrate were from Thermo Scientific (Rockford, IL). Complete, EDTA-free protease 
inhibitor cocktail was obtained from Roche (Indianapolis, IL). A23187, calcium 
ionophore, was from Calbiochem (San Diego, CA). APT1 inhibitor, palmostatin B 
was purchased from EMD Millipore (Billerica, MA). [9,10-
3
H(N)]-palmitic acid was 
purchased from Perkin Elmer (Boston, MA, USA). Anti-Munc13-4 monoclonal 
antibody was generated using the domain C as antigen and given as a generous gift 
from Dr. Christian Wimmer (Basel Institute for Immunology, Basel, Switzerland). 
Recombinant human IKKβ, Amplex® red cholesterol assay kit, and Sypro®Ruby 
protein gel stain were from life technologies (Carlsbad, CA). QuikChange
TM
 
site-directed mutagenesis kit was from stratagene cloning systems (La Jolla, CA). 
β-octylglucoside was purchased from Research Products International Corp. (MT. 
Prospect, IL). PKCα was obtained from SignalChem (Richmond, BC, Canada). All 
lipids were obtained from Avanti Polar Lipids (Alabaster, AL). 
1-palmitoyl-2-oleoyl-phosphatidylethanolamine (PE), 1-palmitoyl-2-oleoyl 
phosphatidylcholine (PC), and 1,2-dioleoyl phosphatidylserine (PS), 
N-(7-nitro-2-1,3-benzoxadiazol-4-yl)-1,2-dipalmitoyl phosphatidylethanolamine 
(NBD-PE) and N-(lissamine rhodamine B sulfonyl)-1,2- dipalmitoyl 
phosphatidylethanolamine (Rhodamine-PE), diacylglycerol (DAG). Amplex Red 
Cholesterol Assay Kit was purchased from Invitrogen, Life Technologies (Grand 
Island, NY). BMS-345541 and TPCA-1 were from Sigma-Aldrich  
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Methods 
Mutagenesis in SNAP-23/Syntaxin-2 cDNA sequence: Constructs of 
syntaxin-2/SNAP-23 and VAMP-8 were designed and made by Dr. Michael C. 
Chicka in the Whiteheart laboratory (70). The detailed information is as below: DNA 
encoding the open reading frames of rat syntaxin-2 (amino acids 1-290; provided by 
J.M. Edwardson, University of Cambridge) and SNAP-23 (provided by E. R. 
Chapman, University of Wisconsin) was inserted into the pRSFDuet expression 
vector (Merck Millipore, Billerica, MA). All cDNAs were checked for variants and 
corrected to wild-type sequence if necessary. DNA encoding mouse VAMP8 (amino 
acids 1-101; provided by Wan Jin Hong, Institute of Molecular and Cell Biology, 
Singapore) was inserted into the pPROEX expression vector (Life Technologies, 
Grand Island, NY).  
To replace the Ser95 residue of SNAP-23 with a negative charge amino acid, 
Asp or Glu in the construct of syntaxin-2/SNAP-23 by site-directed mutagenesis.  
 
For the Asp mutation primers: 
Forward primer sequence: 
5’ ccaagaactttgaggatggaaagaactataaggc 3’ 
Reverse primer sequence:  
5’ gccttatagttctttccatcctcaaagttcttgg3’ 
 
For the Glu mutation primers: 
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Forward primer sequence 
5’ ccaagaactttgaggagggaaagaactataaggc 3’ 
Reverse primer sequence 
5’ gccttatagttctttccctcctcaaagttcttgg3’ 
 
For the Ala mutation primers: 
Forward primer sequence 
5’ ccaagaactttgaggctggaaagaactataaggc 3’ 
Reverse primer sequence 
5’ gccttatagttctttccagcctcaaagttcttgg3’ 
PCR conditions were as follows: 1 cycle at 95 °C for 30 sec, then 16 cycles at (95 °C 
for 30 sec, 57 °C for 1 min, 68 °C for 12 min) and 1 cycle at 68 °C for 12 min. 
Amino acid substitutions were introduced using the site-directed mutagenesis 
(Stratagene). The sequence of clones was further confirmed by DNA sequencing at 
Davis Sequencing (Davis, CA).  
Recombinant Protein Production: All syntaxin-containing complexes and VAMP-8 
were overexpressed in the Rosetta Escherichia coli cells (Novagen) and target 
proteins with His6 tag were purified from cell lysates by Ni
2+
-NTA agarose 
chromatography.  
For production of recombinant wildtype or mutated proteins 
(syntaxin-2/SNAP-23 and VAMP-8) , purified plasmid DNAs were transformed into 
the Rosetta Escherichia coli cells (Novagen) which harbor a plasmid (pRARE) 
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containing rare tRNA sequences (Novagen, Gibbstown, NJ). The colonies were 
amplified by culturing in 2,000 mL LB media containing 50 μg/mL kanamycin and 35 
μg/mL chloroamphenicol (LB/kan/cam) overnight at 37°C, recovered by 
centrifugation, and inoculated into 8 L of SuperBroth in BioFlo 3000 fermentor (New 
Brunswick Scientific Co., INC., NY). Recombinant protein production was induced 
by adding 0.8 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 4 hr at 37°C. The 
cells were harvested by centrifugation at 6,000 × g for 5 min and washed once in 
ice-cold PBS. The bacterial pellet was weighed and resuspended in breaking buffer. 
The cells were solubilized by 2% TritonX-100 for1 hr rotation at 4°C and sonicated 
on ice. The lysate was subjected to ultracentrifugation at 100,000 × g for 1 hr. The 
supernatant was filtered using 0.2 μm nylon filter (Fisher Scientific) and applied to 
Ni
2+
-NTA agarose chromatography. The purified recombinant proteins were eluted in 
25 mM HEPES, pH7.4, 400 mM KCl, 500 mM imidazole, 10%w/v glycerol, 5 mM 
β-mercaptoethanol and 1% w/v β-octylglucoside at 4°C and the aliquots were stored 
at -80°C. 
Preparation of SNARE-Containing Proteoliposomes: All lipids were from Avanti 
Polar Lipids (Alabaster, AL). To reconstitute the v- or t-SNAREs into vesicles, 
phospholipids were mixed with protein in the presence of the detergent 
β-octylglucoside (32). After rapid dilution, the concentration of β-octylglucoside was 
below of the critical micellar concentration (CMC). Once the proteoliposomes were 
formed, the proteoliposomes were dialyzed overnight to get rid of detergent 
β-octylglucoside. And then the vesicles were concentrated by flotation in a density 
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gradient (Accudenze). For making t-SNARE proteoliposomes, t-SNAREs were 
reconstituted in 30% PE, 55% PC and 15% PS, and all phospholipids were added into 
glass tubes, which were soluble in chloroform. After mixing all the lipids, chloroform 
was then removed in N2 evaporator (Parker Balston gas generator, Haverhill, MA) in 
the laboratory of Dr. Andrew Morris (University of Kentucky, Lexington, KY). The 
residual chloroform was removed by high vacuum for at least 1 hr. Then the 
phospholipids were resuspended by t-SNAREs, which were in protein elution buffer 
(25mM HEPES, 400 mM KCl, 500mM imidazole, 10% glycerol, 5 mM β-ME, 1% 
β-octylglucoside). The solution becomes clear because of the detergent. 2-fold 
volumes of dialysis buffer were added into tubes of vesicle, so that 0.33% (w/v) 
β-octylglucoside was below its CMC (0.73%). To obtain detergent-free membrane 
vesicle, the proteoliposomes were dialyzed in dialysis buffer (25 mM HEPES, 200 
mM KCl, 10% Glycerol and 1mM dithiothreitol (DTT), pH 7.4). After dialysis, 
proteoliposomes will be concentrated using Accudenz gradient ultracentrifugation at 
100, 000 × g at 4 °C for 4-6 hr, concentrated proteoliposomes will be collected from 
the 0/30% Accudenz interface.  
v-SNAREs were reconstituted using a mix of 27% PE, 55% PC, 15% PS, 1.5% 
NBD-PE, (donor), and 1.5% Rhodamine-PE, (acceptor). All the steps were the same 
with t-SNARE proteolipsomes. 
v-SNARE (VAMP-8) and t-SNARE (SNAP-23 + syntaxin-2) vesicles were 
reconstituted to give ~60 copies and ~95 copies per vesicle, respectively. Syntaxin-2 
was a surrogate for syntaxin-11, as we cannot produce recombinant syntaxin-11 with 
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the appropriate acylation. 
Fusion Assays: As shown in Figure 2-1, 10 μL t-SNARE vesicles were incubated 
with 0.5 mM ATP, 10 mM MgCl2, and IKK (1.0 μg/reaction) at room temperature 
(RT). v-SNARE vesicles were incubated separately at RT. After 60 min, v- and half of 
the t-SNARE vesicles were mixed in 25 mM HEPES pH 7.4, 100 mM KCl, 1 mM 
DTT, and fusion was monitored at 37°C. Calcium (1 mM final) was added at t=20 
min. The increase in NBD fluorescence was measured using a Bio-TEK FLx800 
Microplate Fluorescence Reader and KC4 software with data acquisition every 1.5 
min. After 60 min, 15 μL of 5% n-dodecyl-β-D-octylglucoside was added to obtain 
the maximum fluorescence. Fusion was plotted as the percent of maximum 
fluorescence over time. Some aliquot of t-SNAREs were analyzed by western blotting 
using anti-phospho-Ser95 and anti-SNAP-23 antibodies. For inhibitor study, 5 μM 
BMS-345541 or 0.5 μM TPCA-1 were added to the t-SNARE mixture containing 1.0 
μg IKK and fusion was monitored after 60 min. 
Mouse Platelet Preparation: Mice were euthanatized by CO2 inhalation. After 
thoracic region were exposed, blood was collected from a ventricle by 1 mL syringe 
filled with 100µL 3.8% sodium citrate and then mixed with PBS (pH 7.4) by 1:1 ratio, 
and incubated with prostaglandin I2 (PGI2) (10 ng/mL; 5min), followed by 
centrifugation at 237 × g for 10 min at room temperature (RT). Platelet-rich plasma 
(PRP) was carefully recovered avoiding disrupting red blood cell layer. Platelets were 
pelleted at 483 × g for 10 min at RT. The pellets were resuspended in HEPES/Tyrode 
buffer (20 mM HEPES/KOH, pH 6.5, 128 mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 0.4 
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mM NaH2PO4, 12 mM NaHCO3, 5 mM D-glucose) supplemented with 1 mM EGTA, 
0.37 U/mL apyrase, and 100 ng/mL prostaglandin I2 (PGI2) (Ann Arbor, MI). Platelets 
were washed and resuspended in HEPES/Tyrode buffer (pH 7.4) without EGTA, 
apyrase, or PGI2. Platelets were counted with a Z2 coulter particle count and size 
analyzer (Beckman/Coulter, Fullerton, CA) and adjusted to 1~2 × 10
9
/mL for further 
use. 
Human Platelet Preparation: Fresh human platelets from healthy donors were 
isolated and adjusted to 1 × 10
9
/mL. Blood was collected into acid citrate dextrose 
(ACD) collection tubes at UK clinic. After collection, all the blood were transferred 
into 50mL conical tubes and centrifuged at 250 × g for 20 min at RT to separate red 
blood cells from platelet rich plasma (PRP). The PRP was carefully transferred to a 15 
mL tube containing 0.37 units/mL apyrase, 100 ng/mL PGI2 for 10 min at RT, and 
then centrifuged at 900 × g for 10 min. The pellets, platelets, were resuspended with 
HEPES-Tyrode’s buffer pH 6.5 containing 0.37 units/mL apyrase, 100 ng/mL PGI2 
for 10 min at RT. Finally, washed platelets were obtained by centrifugation at 850 × g 
for 8 min and resuspended with HEPES-Tyrode’s buffer pH 7.4. The concentration of 
platelets was measured by a Z2 coulter particle counter (Beckman/Coulter, Fullerton, 
CA) and adjusted to the indicated concentrations.).  
Subcellular Fractionation of Platelets: Subcellular fractionations were performed 
by following the Whiteheart laboratory protocol (50). Washed human platelets (1 × 
10
9
/mL) were resuspended in HEPES/Tyrode buffer (pH 7.4) with protease inhibitors, 
and were disrupted by 5 freeze-thaw cycles to break plasma membrane. Plasma 
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membrane protein was spun at 100,000 × g for 1 hr at 4°C. The supernatant, cytosol 
protein, was kept, and plasma membrane was treated with 1% TritonX-100 and kept 
on ice for 30 min. After TritonX-100 treatment, samples were subjected to 100,000 × 
g centrifugation for isolating detergent soluble and insoluble fraction. The subcellular 
fractionations were subjected to SDS-PAGE and western blotting analysis. 
Platelet Aggregometry: Washed platelets (500 µL, 4 × 10
8
/mL) were warmed and 
stirred by a metal stirring bar with 800 rpm at 37°C in a siliconized glass cuvette 
(Chrono-log, Havertown, PA) as shown in Figure 2-2. The assay was carried out in 
Model 460Vs Lumi-Dual aggregometer (Chrono-log). Agonists were added into the 
washed platelets, and the data were collected via a Model 810 Aggro/Link computer 
interface and Aggro/Link software (Chrono-log). 
Platelet ATP Release: ATP release from dense core granules were carried out using 
aggregometer. Washed platelets (475 μL) were preincubated with Chrono-Lume® 
reagent (Chrono-log) containing luciferin and luciferase for 2 min at 37°C under 
stirring condition at 800 rpm. The agonists were added into the reaction to initiate 
ATP release upon platelet activation. The product of luciferin by ATP-driven 
luciferase, was monitored by absorption at 560 nm using the same interface and 
software as platelet aggregation assay. 
Metabolic Labeling With [
3
H]-Palmitate in Platelets: For metabolic labeling, 
washed platelets were incubated with 200 µCi/mL [9,10-
3
H(N)]-palmitic acid for 1 or 
2 hr at 37°C, in HEPES-Tyrode’s buffer, pH 7.4 in presence of 1% fatty acid-free 
bovine serum albumin (BSA). For other experiments, platelets were from human PRP 
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obtained from the Kentucky Blood Center as units (Lexington, KY). The platelet 
isolation from PRP steps were the same as fresh platelet isolation as described in 
Human Platelet Preparation. 
Platelet [Ca
2+
] Measurements using Fura-2AM: Intraplatelet calcium was 
measured using Fura-2-acetoxymethyl ester (Fura-2AM) and experiment procedure 
was modified from the Whiteheart laboratory protocol- Ren et al. (54). Washed 
platelets (4 × 10
8
/mL) in HEPES-Tyrode’s buffer (pH7.4) were incubated in presence 
or absence of cerulenin at 37 °C for 1 hr. Then 1 µM Fura-2AM (Invitrogen) was 
added into platelets at 37 °C for 1 hr. After incubation, the Fura-2 loaded platelets 
were resuspended in HEPES-Tyrode’s buffer (pH7.4). The platelet concentration was 
adjusted to 2 × 10
8
/mL. 0.7 mM CaCl2 and 750 µL platelets were added to siliconized 
cuvettes and stimulated with 0.1 U/mL thrombin and constant stirring. Fluorescence 
was analyzed by excitation at 340 nm and 380 nm, and emission was measured at 509 
nm using a model LS55 Luminescence Spectrometer (Perkin-Elmer Cetus). The ratio 
of emissions was calculated simultaneously using FL WinLab4.0 software 
(Perkin-Elmer Cetus) and used to calculate free calcium levels.  
Cholesterol Depletion of Platelet: For cholesterol depletion, washed platelets were 
incubated with, a cholesterol depletion reagent, 10 mM methyl-β-cyclodextrin 
(MβCD) at 37°C for 30 min. After incubation, platelets were washed and resuspended 
at 4 × 10
8
/mL in HEPES-Tyrode’s buffer (pH7.4). The pretreated platelets were used 
for aggregation by agonists and ATP release assay. Half parts of platelets were lysed 
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in lysis buffer containing 1% TritonX-100, and subjected to sucrose-gradient 
centrifugation for lipid raft isolation. 
Cholesterol Assay: Washed mouse platelets (5 × 10
8
) or washed human platelets (1 × 
10
8
) were resuspended in in HEPES-Tyrodes Buffer (pH 7.4). Lipids were extracted 
with 400 µL chloroform: isopropanol:NP-40 (7:10:0.1) by vortexing and sonication, 
and then the extracts were centrifuged at 15, 000 × g at RT. The liquid was transferred 
to a new tube, and dried to remove organic solvent. The cholesterol assay was set up 
as follow: the reagents from Amplex Red Cholesterol Assay Kit (Life technologies). 
The dried lipids were dissolved in 1X Reaction Buffer by sonication and vortex 
mixing. Cholesterol reference standard was diluted to produce cholesterol 
concentration curve (0 to 8 µg/mL). In the reaction, it contained 300 μM Amplex Red 
reagent containing 2 U/mL HRP, 2 U/mL cholesterol oxidase and 0.2 U/mL 
cholesterol esterase. Once diluted samples were added into reaction, it took 30 mins 
for incubation at 37 °C. Fluorescence was measured in reader at excitation of 544 nm 
and emission at 590 nm.  
Platelet Lysis and Sucrose-Density-Gradient Fractionation: Washed platelets (1 × 
10
9
) was lysed with 2× lysis buffer (50 mM MES (pH 6.5), 300 mM NaCl, 2% 
CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate), protease 
inhibitor cocktail, and 4 mM Na3VO4) and mixed with 80% sucrose to make 40% 
sucrose-lysate mixture. The mixture was laid into ultracentrifuge tube (12 mL; 14 mm 
× 89 mm Beckman), and then 30% sucrose, 5% sucrose were laid sequentially on the 
top. The centrifuge tubes were applied on the rotor and centrifuged at 200,000 × g at 
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4 °C. After centrifugation, the samples were collected in 1mL/ fraction by peristaltic 
pump (RAININ Instrument Inc.). Each fraction was concentrated by tricholoracetic 
acid (TCA) precipitation and subjected to western blotting. 
Immunoprecipitation: Washed unlabeled or [
3
H]-labeled platelets (500 µl) were 
warmed at 37°C for 5 min and thrombin was added to activate platelets in stimulated 
group. 1 × 10
9
 platelets were incubated in presence or absence of inhibitor and 
activated with thrombin (0.1 U/mL) , and then lysed with 2× lysis buffer (40 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 2% Triton X-100, 2% 
sodium deoxycholate, 5 mM sodium pyrophosphate, 2 mM Na3VO4, and protease 
inhibitor cocktail). The lysates were kept in ice and clarified by centrifugation with 
13,000 RPM, for 5 min and the supernatants were incubated with rabbit IgG and 
Protein A-Sepharose 4 (PAS) Fast Flow (GE Healthcare, Piscataway, NJ) for 
pre-clear step and the PAS beads were discarded. And then antibodies of syntaxin-11 
or SNAP-23 were incubated with platelet lysates for 2 hr at 4°C, and after 3 time 
wash, PAS beads were added into platelet lysates for 1 hr rotation at 4°C, and then 3 
time wash. Proteins were eluted with 2×SDS loading buffer for 8 min at 95°C. For 
[
3
H]-labeled platelets, Proteins were eluted with 2×SDS loading buffer (no 
β-mercaptoethanol or DTT) for 8 min at 95°C. The immunoprecipitates were 
analyzed by SDS-PAGE and western blotting. 
Immunoprecipitation (IP)-Acyl-Biotinyl-Exchange (ABE) Experiments: IP and 
ABE experiments were performed for detecting acylation of t-SNARE proteins as 
shown in Figure 2-3, and protocol are modified from Brigidi et al.(171). For cerulenin 
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or palmostatin B treated experiments, washed platelets (1 × 10
9
/mL) were incubated 
in presence or absence of drugs for 2 hr, and then washed and resuspended in 
HEPES/Tyrode buffer (pH 7.4). After treatment, platelets were lysed with ice cold 1x 
Lysis Buffer (with protease inhibitors, 1 mM PMSF, 2 mM Na2VO4, 2% Triton 
X-100, 2% sodium deoxycholate, 50 mM Tris-HCl pH7.5, 150 mM NaCl) containing 
50 mM NEM. The Eppendorf tubes were rotated at 4°C for 1hr. Anti-syntaxin-11 and 
anti-SNAP-23 antibodies were added into lysates and incubated at 4°C for overnight. 
After overnight-incubation, PAS was pelleted by centrifugation at 500 × g for 1min 
and then washed three times with 1x Lysis Buffer containing protease inhibitors to get 
rid of NEM. IP samples with PAS beads were treated with 0.1M Hydroxylamine (HA) 
containing Lysis Buffer (pH7.4) for 30 min rotation, which removes palmitate from 
cysteines, and ready for biotinylation with BMCC-biotin. At the same time, the 
omission of HA cleavage was used as a negative control. After cleavage step, IP 
samples with PAS beads were incubated with 1.5 μM BMCC-biotin for 1 hr at 4°C to 
for biotinylation formation. To get rid of unreacted BMCC-biotin, PAS beads were 
resuspended in Lysis Buffer, and proteins were eluted by 2× SDS-PAGE-Loading 
buffer, and then samples were boiled at 95°C for 8 min. 
Human Platelet Fluorescence-Activated Cell Sorting (FACS) Analysis: Washed 
human platelets were pre-treated with cerulenin as these concentration: 0 μM (as 
control group), 56 μM, 167 μM and 500 μM and incubated at 37°C for 2 hr. 1 mM 
Ca
2+
 was added into platelets and incubated for 30 min prior to stimulation of platelets 
by agonists. 0.1 U/mL thrombin or 4 μM A23187 was used to stimulate platelets for 3 
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min, which were stopped by hirudin, and then FITC anti-human CD62P, P-selectin 
was added into platelets respectively for 10 min incubation. Then transfer samples to 
FACS tubes and ready for analysis by flow cytometry.  
In the depletion of cholesterol study, washed platelets were pre-treated with 10 
mM methyl-β-cyclodextrin (MβCD) for 15 min at 37°C, and then FACS were carried 
on with MβCD treated platelets. 
Purified t-SNARE Preparation for Mass Spectrometry Analysis: Syntaxin-11 and 
SNAP-23 from washed platelets were purified by IP experiments and modified by 
IAA after HA cleavage. After trypsin digestion, peptide fragments from the two 
t-SNAREs were fractionated by HPLC and fragmentation in a TOF/TOF spectrometer 
used to identify acylation sites as indicated in Figure 2-4 
Liquid Chromatography-electrospray Ionization-tandem Mass Spectrometry 
(LC-ESI-MS/MS) Analysis: All mass spectra reported in this study were acquired by 
the University of Kentucky Proteomics Core Facility. Syntaxin-11 and SNAP-23 from 
washed platelets were purified by IP experiments and modified by IAA after HA 
cleavage. After trypsin digestion, tryptic peptides were extracted, concentrated and 
injected for nano-LC-MS/MS analysis as previously described in Yang et al.(172). 
LC-MS/MS analysis was performed using an LTQ-Orbitrap mass spectrometer 
(Thermo Fisher Scientific, Waltham, MA) coupled with an Eksigent Nanoflex 
cHiPLC™ system (Eksigent , Dublin, CA) through a nano-electrospray ionization 
source. The peptide samples were separated with a reversed phase cHiPLC column 
(75 μm x 150 mm) at a flow rate of 300 nL/min. Mobile phase A was water with 0.1% 
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(v/v) formic acid while B was acetonitrile with 0.1% (v/v) formic acid. A 50 min 
gradient condition was applied: initial 3% mobile phase B was increased linearly to 
40% in 24 min and further to 85% and 95% for 5 min each before it was decreased to 
3% and re-equilibrated. The mass analysis method consisted of one segment with 
eight scan events. The 1st scan event was an Orbitrap MS scan (300-1800 m/z) with 
60,000 resolution for parent ions followed by data dependent MS/MS for 
fragmentation of the 7 most intense ions with collision induced dissociation (CID) 
method.  
MS/MS Protein Identification: The LC-MS/MS data were submitted to a local 
mascot server for MS/MS protein identification via Proteome Discoverer (version 1.3, 
Thermo Fisher Scientific, Waltham, MA) against a customized database containing 
syntaxin-11 or SNAP-23. Typical parameters used in the MASCOT MS/MS ion 
search were: trypsin digestion with maximum of two miscleavages, cysteine 
carbamidomethylation, cysteine nethylmaleimide modification, methionine oxidation, 
a maximum of 10 ppm MS error tolerance, and a maximum of 0.8 Da MS/MS error 
tolerance. A decoy database was built and searched. Filter settings that determine false 
discovery rates (FDR) were used to distribute the confidence indicators for the peptide 
matches. Peptide matches that pass the filter associated with the strict FDR (with 
target setting of 0.01) were assigned as high confidence. For MS/MS ion search, 
proteins with two or more high confidence peptides were considered unambiguous 
identifications without manual inspection. Proteins identified with one high 
confidence peptide were manually inspected and confirmed. 
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Anti-syntaxin-11 Antibody Purification: For affinity purification of the 
anti-syntaxin-11 antibody; purified syntaxin-11 was coupled to 2 mL CNBr-activated 
Sepharose beads for overnight incubation at 4°C. The column was washed with 20 
volumes of PBS to remove unbound protein. 10 mL of 100 mM ethanolamine (pH 8.0) 
was added and incubated for 6 hr at 4°C with gently rocking to block any residual 
reactive groups left on the column. After washing the column with 10 volumes of 
PBS, the antibody purifying column was ready to be used. Five milliliters of sera were 
diluted, 1:1, with TBS and filtered through a 0.2 μm filter. The filtered sera was 
loaded onto the column and incubated overnight at 4°C. To wash out the unbound 
antibody, the column was extensively washed with TTBS containing1% Tween-20 
until the A280 was less than 0.02. The column was eluted with 10 volumes of Elution 
Buffer. One milliliter fractions were collected into 1.5 mL microtubes containing 50 
μL the Neutralizing Buffer (1M Tris, pH 8.0). Antibody was collected, concentrated, 
dialyzed against PBS, and stored as aliquots at -20°C. The affinity-purified 
anti-syntaxin-11 antibody was used for immunoprecipitation of endogenous 
syntaxin-11 from platelet extracts in the dissertation. 
Triton X-114 Phase Separation: Triton X-114 is the nonionic detergent solution, and 
can be homogeneous at 0°C, but separated into an aqueous phase and a detergent 
phase above 20°C (173). Hydrophobic proteins will go into Triton X-114, the 
detergent phase; at the same time, hydrophilic proteins will be in aqueous phase. 
Triton X-114 phase separation was designed for platelets membrane protein 
separation, Platelet membrane proteins can be lysed in Triton X-114, hydrophilic 
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proteins were found in the aqueous phase, whereas hydrophobic proteins, such as 
integral proteins or lipid-anchored proteins were recovered in the detergent phase. 
Experiment procedure was modified from Kutzleb et al. (173). 
Platelet membrane pellet (1 × 10
9
 platelets) were lysed in 2% Triton X-114 and 
treated with or without 0.3 M HA at 4°C for 1 hr. The lysis of membrane pellets was 
transferred to a microcentrifuge tube and then subjected to centrifugation for 15 min 
at 10,000 × g at 4°C to get rid of insoluble fraction. Supernatant was taken out in to a 
fresh microcentrifuge tube and incubated at 37°C for 3 min for phase partitioning and 
then subjected to centrifugation for 1 min at 10,000 × g at RT. The upper (aqueous) 
phase and the lower (detergent) phase were separated. Re-extractions of aqueous and 
detergent phase were done for additional twice for further purification. Extracted 
samples were precipitated by TCA to get rid of Triton X-114, were subjected for 
SDS-PAGE gel and then probed for analysis with anti-syntaxin-11, anti-SNAP-23, 
anti-VAMP-8, and anti-syntaxin-4 antibodies. 
Statistics Analysis: Data acquired in the dissertation were analyzed and performed 
using GraphPad Prism 6. Two-way ANOVA or Student’s t-tests were performed. P 
values < 0.05 were considered significant.
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Figure 2-1 Proteoliposome Fusion Assay 
The in vitro fusion assay is illustrated. Labeled v-SNARE (VAMP-8) proteoliposomes 
with Förster resonance energy transfer (FRET) pair (NBD and rhodamine, as a donor 
and acceptor respectively) were mixed with unlabeled t-SNARE 
(syntaxin-2/SNAP-23) liposomes. During the membrane fusion happening, the 
distance between NBD and rhodamine was increased and thus more NBD signal was 
recorded. Fusion data were normalized to the maximum donor fluorescence as 
described in Methods. 
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Figure 2-2 Schematic of Platelet Aggregation Detection by Aggregometry 
In the aggregometer, washed platelets (4 × 10
8
/mL) are added and stirred in a cuvette 
at 37°C until a steady baseline is achieved. When an agonist is added, the response 
recorded that the platelets aggregate and absorb less light. So the transmission 
increases and this is detected by the photocell. The aggregometer is calibrated by: a 
cuvette containing washed platelets which equates to 0% light transmission. A second 
cuvette containing dH2O is set to 100% light transmission. Upon platelets stimulated 
by agonists, the aggregation curve will be recorded by aggregometry. 
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Revised from J Vis Exp. 2013 Feb 18;(72) 
Figure 2-3 Schematic of the IP-ABE Assay to Purify and Detect Palmitoylation 
(1)Washed platelets were lysed by RIPA buffer, and proteins were purified using a 
specific antibody, and immobilized on protein A-sepharose beads . The purified target 
protein was then treated with NEM to block free thiol (-SH) groups along unmodified 
cysteines (C). Then HA pH7.4 (2) was used to specificly cleave thioester bonds at 
acylated cysteines and generate newly free reactive thiol group (-SH). Next step, the 
target protein was (3) treated with biotin-BMCC, a sulfhydryl-reactive biotinylation 
reagent resulting in specific biotinylation of the newly free cysteine. Finally, (4) the 
biotinylated target protein was eluted in 2% SDS lysis buffer. The acylation of target 
protein was specificly biotinylated and detected with SDS-PAGE gel, and western 
blotting with streptavidin-HRP to detect for acylation of the purified t-SNARE 
proteins.   
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Figure 2-4 Schematic of Mass Spectrometry Analysis of Acylation Sites 
Washed platelets were lysed by RIPA buffer, and proteins were purified using a 
specific antibody, and immobilized on PAS. The purified target protein was then 
treated with NEM to block free thiol (-SH) groups along unmodified cysteines (C). 
Then HA pH7.4 (2) was used to specificly cleave thioester bonds at acylated cysteines 
and generate newly free reactive thiol group (-SH). Next step, the target protein was 
(3) treated with iodoacetamide, an alkylating agent resulting in specific alkylation of 
the newly free cysteine. Finally, (4) the alkylated target protein was resuspended in 2% 
SDS lysis buffer, purified by SDS-PAGE gel and stained by Coomassie blue. Target 
proteins were recovered and in-gel digested by trypsin overnight at 37°C. (5) The 
digested samples were sent to Mass Spectrometry for analysis. 
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Chapter Three: SNAP-23 Phosphorylation in Platelet Secretion 
Introduction 
In platelets, SNARE proteins mediates membrane fusion through several steps: 
targeting, docking, priming and membrane fusion. Regulatory proteins, such as 
Munc13-4 and Munc18-2, play an essential role in enhancing membrane fusion 
(66,69,70,73). In addition, PTM, such as phosphorylation, regulates 
SNARE-mediated membrane fusion. Phosphorylation of SNAREs has been reported 
in platelets and has been proposed to be regulated by an array of kinase: e.g., PKC, 
PKA, IKK and SNAK (80,83,91,174,175). As one Ser/Thr kinase, PKCα regulates 
many aspects of platelet function, such as activation and thrombus formation (176). 
PKC can phosphorylate SNAREs and regulatory proteins, such as SNAP-23, 
SNAP-25, and Munc18-1, thus promoting exocytosis (82,177). Phosphorylation of 
SNAP-23 at Ser95 and Ser120 has been reported in stimulated mast cells and platelets 
(83). IKK is the relevant kinase in mast cells and appears to promote SNARE 
complex (syntaxin-4/SNAP-23/VAMP-8) formation in nongenomic way (99). In 
platelets, aggregation and granule secretion are inhibited when platelets are treated 
with IKK-specific inhibitors (80). Mice given IKK inhibitors had significantly 
prolonged bleeding times showing that IKK activity is important for hemostasis in 
vivo (80). Platelet-specific IKKβ knockout mice also had a defect in platelets 
secretions and prolonged bleeding. Phosphorylation of SNAP-23 and IκB were 
decreased in IKKβ
-/-
 platelets. Combining IKK inhibitor studies and data from the 
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IKKβ-specific knockout model, it is clear that IKK is important in the regulation of 
platelet secretion and hemostasis. These defects correlate with the loss of SNAP-23 
phosphorylation. However, since all those work were done in animal models or 
platelets, there is no direct evidence showing that IKK-mediated phosphorylation of 
SNAP-23 is important for membrane fusion. The first part of my dissertation directly 
addresses the role of IKK-mediated SNAP-23 phosphorylation in membrane fusion 
using a liposome fusion assay, purified SNAREs and kinases, and phosphomimetic 
mutants. I will additionally seek to determine if IKK directly phosphorylates 
SNAP-23 or promotes a PKC dependent phophorylation. 
Results 
IKK, but not PKC, directly Phosphorylates SNAP-23: In platelets, SNAP-23 
phosphorylation was detected upon activation with several agonists (84). The 
phosphorylation sites were identified in mast cells and platelets and Ser 95 and Ser 
120 appeared to both be modified (83). IKKβ
-/-
 knockout mast cells, SNAP-23 
phosphorylation required IKK (99) and similar results were obtained in platelets (80). 
PKC is the kinase involved in regulating platelet secretion, cytoskeleton reorgnization 
and spreading, thrombus formation, and platelet activation (178-180). SNAP-23 can 
be phosphorylated by PKC in vitro (84); however, there was no direct evidence to 
show whether IKK or PKC phosphorylates SNAP-23 in vivo. To answer this question, 
kinase assays were performed. Equal amounts of IKK and PKC were incubated with 
t-SNARE complex, syntaxin-2/SNAP-23 for 1 hr, and phosphorylation of SNAP-23 
was monitored by Western blotting. As shown in Figure 3-1, the degree of SNAP-23 
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phosphorylation at Ser95 by IKK was 50 fold higher than that by PKC, indicating that 
SNAP-23 (specifically Ser95) is the substrate of IKK rather than of PKC. In the 
negative control groups, SNAP-23 was not phosphorylated when either kinase was 
omitted.  
Phosphorylation of SNAP-23 Plays a Role in Membrane Fusion: In Figure 3-1, 
IKK appears to directly phosphorylate SNAP-23 at Ser95, while PKC does not. Karim 
et. al., showed that SNAP-23 phosphorylation was diminished and platelet granule 
secretion was inhibited when the IKK-specific inhibitors, BMS-345541 and TPCA-1 
were used. In IKKβ
-/-
 platelets, SNAP-23 was not phosphorylated and the platelets 
had a secretion defect (80). These in vivo and ex vivo results suggest that IKK, 
through its effects on SNAP-23, is important for hemostasis and thrombosis. In mast 
cells, SNAP-23 phosphorylation can be regulated by IKK and is important for 
degranulation (99). However, it is unclear what effect phosphorylation has on 
SNAP-23 activity, specifically in its role in membrane fusion. To address this 
question and to determine whether SNAP-23 phosphorylation promotes SNARE 
complex formation, t-SNARE complex (syntaxin-2/SNAP-23, syntaxin-2 is a 
surrogate for syntaxin-11) we used an in vitro proteoliposome fusion assay system. 
Proteoliposomes, containing the t-SNAREs, were pre-incucbated with IKK and then 
mixed with v-SNARE (VAMP-8) proteoliposomes and fusion was monitored by the 
time-dependent increase in dequenching of the NBD/rhodamine lipid pair Aliqots of 
t-SNARE proteoliposomes probed for SNAP-23 phosphorylation by Western blotting 
with a phosphopeptide-specific antibody. SNAP-23 was clearly phosphorylated by 
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IKK, and the phosphorylation was blocked by addition of either BMS-345541 or 
TPCA-1. SNAP-23 phosphorylation was not detected when IKK or the t-SNARE 
were omitted (Figure 3-3). Membrane fusion did not occur when the t-SNAREs were 
omitted showing that the increase in fluorescence truly reflected a SNARE-dependent 
process. Inclusion of IKK enhanced the initial rates of proteoliposome fusion and this 
enhancement was blocked by addition of either BMS-345541 or TPCA-1 (Figure 3-2). 
These data are consistent with the effects in intact platelets study (80) and suggest that 
IKK-mediated phosphorylation SNAP-23 directly affects its ability to promote 
SNARE-dependent membrane fusion. The effect of the IKK inhibitors verify the need 
tfor IKK activity in this process. 
SNAP-23 Phosphorylation on Ser95 Promotes SNARE Complex Formation and 
Enhances Membrane Fusion: In thrombin-activated platelets and mast cells, more 
than one phosphorylation sites were identified in SNAP-23, and it is demonstrated 
that SNAP-23 is phosphorylated on Ser120 and Ser95 (83). Also, it is shown that IKK 
phosphorylates Ser120 and Ser95 in mast cells and platelets. Due to the instability of 
our phosphor-peptide specific antibody that recognizes modification of Ser120, we 
could not reliably detect SNAP-23 phosphorylation on Ser120. In addition, it is 
possible that other phosphorylation sites are unidentified in activated platelets, and 
thus affect membrane fusion. To further confirm the role of SNAP-23 phosphorylation 
on Ser95 in membrane fusion, site-directed mutagenesis was used to replace Ser95 
with negative charge amino acids (Asp and Glu residues) were used to replace Ser95, 
mimicking a phosphorylation event. Mutation to Ala was used as a negative control. 
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Mutant SNAP-23/syntaxin-2 were purified and reconstituted into proteoliposomes, 
and mixed with VAMP-8 containing proteoliposomes to measure fusion. In Figure 
3-4, proteoliposomes containing mutant SNAP-23 with mutations of Se95 to Asp95 
or Glu95 showed significantly enhanced initial fusion rates as compared to wild-type 
(WT) SNAP-23-containing proteoliposomes. The Ala95 mutant had a fusion rate 
similar to WT SNAP-23. In summary, these data suggest a positive role of 
phosphorylation of SNAP-23 on Ser95, in enhancing membrane fusion.  
Discussion 
In summary, our data supported the pathway in which IKK phosphorylates 
SNAP-23 on Ser95 in platelets, and thus enhances membrane fusion in platelets. From 
our previous work, PKC inhibitors affect SNAP-23 phosphorylation in platelets (80); 
however, Ser95 phosphorylation of SNAP-23 was not identified in PKCα-activated 
platelets (179). Our previous studies suggested that a PKC isoform was upstream of 
IKK, which is consistent with other studies of T- and B-cells (181). SNARE complex 
(syntaxin-11/SNAP-23/VAMP-8) formation and SNAP-23 phosphorylation were 
detected in activated platelets by co-immunoprecipitation and Western blotting; 
however, SNARE complex formation was not detected in platelets pretreated with 
IKKβ inhibitors or in IKKβ
-/-
 platelets, suggesting that SNAP-23 phosphorylation by 
IKK promotes or stabilized SNARE complexes and thus promotes membrane fusion 
upon platelet activation (80). 
From these data, both in vitro and in vivo manipulation of IKKβ activity affects 
platelet secretion and SNAP-23 phosphorylation, suggesting that IKK activity is 
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needed or platelet function. At the same time, SNARE complex formation was 
affected, indicating that phosphorylation of SNAP-23 may be involved in SNARE 
complex formation and membrane fusion in platelets. The data in this chapter confirm 
this point since I showed an enhanced fusion rates in IKK treated, SNARE-containing 
proteoliposomes. However, it is unclear whether phosphorylation of SNAP-23 
precedes SNARE complex formation or follows it. While we can show that IKK can 
phosphorylate monomeric SNAP-23 in vitro, it is not clear what the preferred 
substrate is in vivo. Further studies are required to determine how SNAP-23 is 
phosphorylated -- SNAP-23 monomer, heterodimer syntaxin/SNAP-23, or SNARE 
complex (syntaxin/SNAP-23/VAMP-8). 
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Figure 3-1 PKC and IKK Kinase Affect SNAP-23 Phosphorylation.  
t-SNARE proteoliposomes were incubated with 0.5 mM ATP, 10 mM MgCl2, and 
IKKβ(0.1U/reaction), or PKC (0.1U/reaction) at 30°C for 1 hr. In the PKC group, 
0.1mg/mL DAG (Avanti Polar Lipids), phosphatidylserine (15% PS) and 1mM CaCl2 
were present in 20 mM MOPS buffer pH7.4. Na3VO4 (0.5mM) and 2.5 mM DTT 
were also added into the kinase reactions. t-SNARE mixture was subjected to Western 
blotting using anti-phosph-Ser95 (pSer-95) and SNAP-23 antibodies. Blots were 
quantified and presented as a ratio of Phospho-SNAP-23/Total SNAP-23. Blots 
shown are representative of two independent experiments. 
.   
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Figure 3-2 IKK Enhances Membrane Fusion and Its Inhibition Blocks the Effect 
In Vitro 
SNARE-bearing vesicles, t- and v-SNARE were reconstituted as described in Chapter 
2 “Methods” section. t-SNARE vesicles were incubated with 0.5 mM ATP and 10 
mM MgCl2 and 1μg/ reaction IKKβ with or without IKKβ inhibitors, BMS-345541 (5 
μM) or TPCA-1 (0.5μM) at RT and then were mixed with v-SNARE proteoliposomes. 
The fusion rates were monitored at 37°C as an increase in NBD fluorescence. After 1 
hr, n-dodecyl-β-D-octylglucoside was added to obtain the maximum NBD 
fluorescence and the fusion rates were calculated as the percent of that maximum. The 
data are representative of at least two independent experiments. 
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Figure 3-3 IKK Directly Phosphorylates SNAP-23 and Phosphorylation is 
Blocked by IKK Inhibitors, In Vitro 
Proteoliposomes bearing t-SNAREs were incubated with 1μg/ reaction IKKβ, and 
then treated with or without IKKβ inhibitors, BMS-345541 (5 μM) or TPCA-1 
(0.5μM) or without IKKβ inhibitors for 60 min (as described in Figure 3-2 legend), a 
aliquot of the t-SNARE mixture was subjected to Western blotting using 
anti-phospho-Ser95 (pSer-95) and SNAP-23 antibodies. Blots were quantified and 
presented as a ratio of pSer-95/Total SNAP-23. The data are representative of at least 
two independent experiments. 
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Figure 3-4 Phosphomimetic Residues at Ser95 Affect the Rates of 
SNARE-Mediated Membrane Fusion  
Ser95 in WT SNAP-23 was substituted with Asp, Glu, or Ala and mutant SNAP-23 
were purified and reconsistituted into proteoliposomes. Fusion assays were carried out 
as described in Chapter 2. Muntant SNAP-23/syntaxin-2-bearing proteoliposomes, 
and VAMP-8-bearing vesicles was reconstituted and preincuated at 37°C. After 20 
min preincubation at 37°C, t-SNARE and v-SNARE were mixed and fusion was 
monitored at 37°C. Ca
2+
 (1 mM final concentration) was added to reactions at t=20 
min as indicated. After 60 min, detergent was added to reactions to obtain the 
maximum NBD fluorescence and fusion was plotted as the percent of maximum NBD 
fluorescence over time.  
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Chapter Four: The Role of Acylation in Platelet Secretion 
Introduction 
Platelet exocytosis is clearly critical for hemostasis. Platelets detect blood vessel 
injuries and act as tiny building blocks to form a hemostatic plug. Molecules released 
from platelet granules control the vascular microenvironment underlining why it is 
critical to understand the mechanism and the regulation of the platelet exocytosis. As 
with other secretory processes, platelet secretion is driven by protein-protein 
interactions whereby the SNAREs, v-SNAREs and t-SNAREs, assemble into a 
four-α-helical bundle that mediates membrane fusion between targeting membrane 
and vesicles. There are several SNAREs identified in platelets: v-SNAREs, including 
VAMP-2, -3, -4, -5, -7, -8; and t-SNAREs including, syntaxin-2, -4, -6, -7, -8, -11, 
-16, -17, -18, SNAP-23, -25, -29 (36,48). Previous work showed that VAMP-8, 
syntaxin-11, and SNAP-23 serve as primary SNAREs in platelets because their 
deletion alone leads to a secretion defect (39,50-52,54). Our group and others have 
also identified a number of SNARE regulators: Munc18-b, Munc13-4, Tomosyn-1 
and SLP4s (69,73,78). These regulators are required for granule secretion. However, 
aside from IKK-mediated phosphorylation of SNAP-23, very little is known about 
whether other PTMs affect the platelet secretory machinery and thus exert control on 
exocytosis. In this chapter, I probe the role that acylation plays in controlling two 
primary t-SNAREs, SNAP-23 and syntaxin-11. 
S-acylation is the covalent attachment of an unsaturated fatty acid, palmitate (C16) 
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or other long-chain fatty acids to cysteine residues of proteins via a thioester bond. 
Acylation plays an important role as a membrane anchor and contributes to protein 
localization, protein stability, and protein-protein interactions (106-109). Acylation 
can also promote a protein’s association with lipid rafts. Acylated proteins partition 
into membrane rafts where they are known to mediate cell signaling events (182,183). 
It is also possible that rafts are a site for membrane fusion and granule release 
(90,120,184,185). S-acylation is enzymatically regulated, by PATs and palmitoyl 
thioesterases. Though there are numerous PAT’s, there are only four thioesterases 
identified in mammalian cells: acyl protein thioesterase 1 (APT1), acyl protein 
thioesterase 2 (APT2), palmitoyl protein thioesterase 1 (PPT1), and palmitoyl protein 
thioesterase 2 (PPT2) (102,127). PPT1 and PPT2 were found in lysosomes and play a 
role in degradation of palmitoylated proteins (128).  
Regulated acylation of SNAREs might affect their role in membrane fusion. In 
this chapter, one PAT inhibitor and one palmitoyl thioesterase inhibitor were used to 
study the effects of SNARE acylation in platelets. Cerulenin (2,3 epoxy-4-oxo-7,10 
dodecadienamide) is a natural product inhibitor of fatty acid synthesis and protein 
palmitoylation (157). It irreversibly alkylates cysteines in PATs, preventing 
acyl-enzyme adduct formation (158). It was also shown to inhibit platelet aggregation 
and thrombus formation in vivo (102). Palmostatin B is an inhibitor of β-lactone acyl 
protein thioesterase 1. In the presence of palmostatin B, the proper localization of 
H-Ras and N-Ras ares disrupted, and therefore the signaling pathway is 
down-regulated in nucleated cells (165). 
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As primary t-SNAREs, syntaxin-11 and SNAP-23 lack a stretch of hydrophobic 
residues long enough to serve as a membrane anchor (40). There is no CAAX motif 
found in either sequence, so farnesylation (C15) or geranylgeranylation (C20) are not 
likely to happen. Both t-SNAREs contain cysteine-rich regions: syntaxin-11 has 8 
cysteines, with 6 at its C-terminus (its cysteine-rich regions); and SNAP-23 contains 6 
cysteines, with 5 in its central domain (its cysteine-rich regions). In proteomic 
analysis, Louisa et al. identified 215 high confidence palmitoylated proteins in 
platelets. Syntaxin-11 is one of the novel candidates. SNAP-23 is known to be 
palmitoylated in its highly conserved cysteine-rich domain between its N- and 
C-terminal SNARE motifs (119). Acylation of SNAP-23 was shown in platelets (102). 
Consistently, Sim et al. showed that PAT inhibitor pre-treatment blocked platelet 
activation in response to several hemostatic agonists (102). Pre-treatment of 
permeabilized platelets with a recombinant thioesterase released SNAP-23 from 
membranes. However, despite these insights, the nature and potential importance of 
t-SNARE acylation, specifically of syntaxin-11 and SNAP-23, is largely undefined in 
platelets. 
In this Chapter, we probed the role of SNARE acylation in platelets using 
chemical and functional assays. We showed that acyl groups were attached via 
thioester linkages that were sensitive to HA. Radiolabeled palmitate was readily 
incorporated into the two t-SNAREs in metabolic labeling experiments suggesting a 
rapid turnover of acyl groups, since there is minimal protein synthesis in resting 
platelets. The extent of acylation did not appear to change upon stimulation or upon 
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passivation. The acylation sites in these two t-SNAREs were identified by mass 
spectrometry and shown to be in the predicted cysteine-rich regions. The t-SNAREs 
did associate with lipid rafts and were enriched in those fractions upon activation. A 
PAT inhibitor blocked stimulated platelet secretion in a time- and dose-dependent 
manner which was reversed by pretreatment with a thioesterase inhibitor. Taken 
together, the data in this chapter show that the two platelet t-SNAREs, Syntaxin-11 
and SNAP-23, are dynamically S-acylated and that this turnover of acylation is 
important for platelet exocytosis. 
Results 
Syntaxin-11 and SNAP-23 are Associated with Membranes and Present in Lipid 
Rafts: Syntaxin-11 and SNAP-23 both lack TMD so we initially sought to determine 
the extent to which they associated with platelet membranes. Membrane fractionation 
was performed and the t-SNAREs in each fraction were assessed by western blotting. 
As shown in Figure 4-1, syntaxin-11 and SNAP-23 were barely detectible in the 
cytosol fractions (S1), but were predominately found in the platelet membrane 
fractions (both Triton X-100 solution (STX) and insoluble (ITX) fractions). This shows 
that the t-SNAREs are mainly membrane associated despite the fact that neither 
possesses a standard TMD. Many of the proteins probed for were solubilized by 
Triton X-100, but there was a fraction of t-SNAREs present in the insoluble (ITX) 
fractions. The insoluble (ITX) fractions were prepared by successive centrifugations (at 
100,000 × g) and they contained cytoskeletal pellet and lipid rafts (186). Consistent 
with previous studies in mast cells (83), we found SNAP-23 associated with this 
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fraction. In mast cells, ternary SNARE complexes (syntaxin-4/SNAP-23/VAMP-2) 
were enriched in lipid rafts during mast cell exocytosis suggesting that rafts may be 
the route of exocytosis (90).  
To determine whether t-SNARE localization changes upon platelet activation, 
lipid rafts were prepared from thrombin activated platelets. Depicted in the diagram 
(Figure 4-2), fractions 9-11 are lipid raft rich fractions. Our data show that 
syntaxin-11, SNAP-23 and VAMP-8 were present in the lipid raft fractions from 
resting platelets (R group) and more SNAREs were present in the rafts prepared from 
activated platelets(S group). Interestingly, there was a significant enrichment of 
VAMP-8 (1.5-fold increase) in the lipid rafts from activated platelets. This together 
with the enrichment of syntaxin-11 and SNAP-23 into the rafts of activated platelets is 
consistent with what is seem in mast cells and suggests that, like in mast cells, the 
lipid rafts may be the site of membrane fusion in platelets. 
Cholesterol Depletion Affects t-SNARE Localization and Platelet Function: Lipid 
rafts are predominantly composed of cholesterol and sphingolipids which are thought 
to exist as aggregates in the lipid bilayer. Cholesterol acts as a spacer between 
hydrocarbon chains of the sphingolipids and aids in the assembly of the raft 
aggregates (168). Depletion of cholesterol can cause proteins to dissociate from lipid 
rafts (187). The data in Figure 4-2 shows that the t-SNAREs are present in lipid rafts. 
To determine whether cholesterol affects this distribution and thus affects platelet 
functions, cholesterol was depleted using methyl-β-cyclodextrin (MβCD). With the 
strategy, total platelet cholesterol was reduced more than 50% (Figure 4-5). 
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Consistently, on the sucrose gradients less SNARE protein (syntaxin-11, SNAP-23 
and VAMP-8) was present in the lipid raft fractions from the MβCD treated -platelet 
compared to untreated controls (Figure 4-3). Accordingly, platelet aggregation and 
ATP release were inhibited in cholesterol-depleted platelets when either A23187 or 
thrombin was used as agonists (Figure 4-4). Since cholesterol deficiency had a 
negative effect on platelets, we asked the converse, does increased cholesterol 
positively affect platelets? For this, platelets from apolipoprotein E (ApoE) knockout 
mice were examined. Total platelet cholesterol was elevated by 35% in ApoE
-/-
 
platelets compared with that in WT platelets (Figure 4-6). Washed platelets from the 
ApoE
-/-
 showed a significantly greater response to stimulation with thrombin. Both 
ATP release and platelet aggregation were hyper-responsive when compared to WT 
mouse platelets. Overall, cholesterol, as one major components of lipid rafts, appears 
to be essential for the raft association of the SNARE and is also important for platelet 
function. 
Acylation and Metabolic Incorporation of [
3
H]-Palmitic Acid into Platelet 
Syntaxin-11 and SNAP-23: In Figure 4-1, syntaxin-11 and SNAP-23 act as integral 
membrane proteins though they lack TMDs. PTMs, such as acylation or prenylation, 
could serve as a lipid anchor. Neither t-SNARE contains a CAAX box but both 
contain a cysteine-rich region that could undergo S-acylation. To address this point, 
we used the IP-ABE assay in which the acyl groups on immuno-precipitated proteins 
are first cleaved with hydroxylamine and then replaced with a biotinylated maleimide 
derivative. Figure 4-7 shows that syntaxin-11 and SNAP-23 from platelets can be 
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detected in this assay. HA specifically cleaves thioester linkage at neutral pH (pH7.5), 
and once removed, the biotin-BMCC covalently modifies the exposed cysteine 
forming a biotinylated protein. In the absence of HA, no biotinylated syntaxin-11 and 
SNAP-23 was detected. These data are consistent with previous studies of these two 
t-SNAREs in other systems (46,112). 
Since platelets are anucleate, they have a very limited capacity for proteins 
synthesis. Most of proteins present in platelets are synthesized at the megakaryocyte 
stage. However, it seems possible that the thioester-linked acylation could turn over in 
resting platelets and those might be dynamic. To address this question, washed human 
platelets were incubated with radioactive palmitate for 1 hr or 2 hr. [
3
H]-Palmitic acid 
efficiently incorporated into both syntaxin-11 and SNAP-23 (Figure 4-8A) in a 
time-dependent manner. To demonstrate that [
3
H]-palmitic acid was incorporated into 
the proteins via a thioester bonds, 2.5% HA at neutral pH was incubated with IP 
samples (syntaxin-11 and SNAP-23) for 30 min prior to electrophoresis and 
autofluorography (Figure 4-8B and C). Both syntaxin-11 and SNAP-23 lost their 
[
3
H]-palmitic acid. Based on the HA-treated samples, the labeled palmitic acid was 
attached to the t-SNARES via an hydroxylamine-sensitive thioester bond. 
Analysis of Acylation Sites in Syntaxin-11 and SNAP-23 by Mass Spectrometry:  
Given our data and the reversibility of S-acylation it is likely that acylation turns over 
in platelets and thus some of the t-SNAREs might be incompletely acylated. 
Therefore, we asked whether all the cysteine of each t-SNARE can be acylated? In 
addition to the cysteine-rich regions of t-SNAREs, there are additional cysteines in 
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syntaxin-11 and SNAP-23 that were also accounted for. To detect each acylation site, 
we used two alkylating reagents, Iodoacetic acid (IAA) and N-ethylmaleimide (NEM), 
in combination with HA treatment and tryptic peptide mass spectrometry. 
Immunopurified proteins were treated with TCEP to reduce any disulfide bonds and 
the free cysteines were covalently modified with NEM. The proteins were then treated 
with HA to cleave thioester-linked moieties and the exposed cysteines were modified 
with IAA. For analysis, the proteins were cleaved with trypsin and subjected to mass 
spectrometry. For syntaxin-11 (n=2), we found evidence of NEM modifications on 
Cys102 (GEVIHNEMC
102
K; monoisotopic m/z = 455.73005 Da; Figure 4-11) and 
Cys157 (QRDNNEMC
157
KIR; monoisotopic m/z = 579.302623 Da; Figure 4-12). No 
other NEM modified peptides were identified suggesting that these two Cysteines 
were either free or involved in a disulfide bond. Upon HA treatment and IAA 
modification, we detected (n=2) two tryptic peptides that were modified: 
KAVQYEEKNPIAAC
275
R (monoisotopic m/z = 507.92435 Da; Figure 4-10) and 
TLIAAC
279
IAAC
280
FIAAC
282
IAAC
283
PIAAC
285
LK (monoisotopic m/z = 759.81061 Da; 
Figure 4-9). These data are consistent with Cys 275, 279, 280, 282, 283, and 285 
being modified by a HA-sensitive thioester-linked, moiety, suggesting that all six 
Cysteines are S-acylated. For SNAP-23 (n=2), NEM modified only Cys112 
(TTWGDGGENSPNEMC
112
NVVSK; monoisotopic m/z = 938.41953 Da; Figure 4-14). 
After HA treatment and IAA modification, we detected (n=2) one modified, tryptic 
peptide: IAAC
79
IAAC
80
GLIAAC
83
VIAAC
85
PIAAC
87
NR (monoisotopic m/z = 728.27869 
Da; Figure 4-13). These data are consistent with Cys 112 being either as free 
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sulfhydryls or in a disulfide bond as part of a homo- or hetero-dimer and Cys 79, 80, 
83, 85, and 87 being modified by a HA-sensitive thioester-linked, moiety, consistent 
with these Cysteines being the site of S-acylation on SNAP-23. 
Acylation of t-SNARE during Platelet Activation and Passivation: Acylation and 
deacylation cycles can be regulated by the opposing actions of PATs and palmitoyl 
thioesterases, which would account for the turnover in acylation that appears to 
describe our results. Is this turnover affected by platelet activation state? To answer 
this point, we examined the incorporation of [
3
H]-palmitic acid into platelet proteins 
under activating conditions, with thrombin, and under passivating conditions with 
PGI2. In Figure 4-15A and B, [
3
H]-palmitic acid incorporation into syntaxin-11 and 
SNAP-23 was unchanged in the presence of PGI2. It is also unchanged when platelets 
were activated with thrombin (0.1U/mL). Acylation was inhibited in cerulenin-treated 
platelets. Cerulenin is an acylation inhibitor in neurons and platelets (102,188). 
Notably, the levels of syntaxin-11 and SNAP-23 protein remained unchanged 
suggested that neither new protein was made nor the SNAREs were degraded during 
the experiment. These data further confirm that the acyl groups are actively turning 
over on the t-SNAREs’ cysteines. To confirm the effects of cerulenin on t-SNARE 
acylation, the IP-ABE assay was performed. Compared to the vehicle-treated group, 
acylation of syntaxin-11 and SNAP-23 was decreased in platelets pre-treated with 
cerulenin (Figure 4-16A and B). Consistently, there is no difference in protein levels 
between cerulenin- and vehicle-treated platelets. Overall, these [
3
H] palmitate 
pulse-chase experiments highlight the reversibility of S-acylation and show that it can 
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be manipulated with the acylation inhibitor, cerulenin.  
PAT and APT Inhibitors Affect Platelet Secretion and Activation: In the studies of 
Sim et al., cerulenin was used to analyze the effects of protein acylation in platelets. 
They showed that cerulenin pretreatment inhibited platelet aggregation (102). We 
expanded on these original studies by looking at other aspects of platelet function. 
Cerulenin treatment (56μM, 167μM, 500μM) had little to no effect on 
thrombin-induced calcium transients as measured with Fura-2 (Figure 4-22). These 
would suggest that cerulenin has no significant effect on the signaling processes that 
facilitate thrombin induced increases in intra-platelet [Ca
2+
], at the concentrations of 
thrombin used. The effect of cerulenin on platelet aggregation was time-dependent; 
platelets, pre-treated with cerulenin, were inhibited within 1 hr (Figure 4-18). 
Cerulenin’s effects on aggregation and ATP release were also dose-dependent (Figure 
4-17). Among three different concentrations of cerulenin, platelets pre-treated with 
500 μM cerulenin displayed the greatest inhibition in ATP release and aggregation. 
Our data confirmed the results of Sim et al. (102). 
To examine the effects of cerulenin of α-granule secretion FACS analysis of 
CD62 (P-Selectin) was used (Figure 4-19). P-selectin exposure, as a metric of from 
α-granule release, in response to thrombin and A23187 was also inhibited by 
cerulenin treatment. The effect of cerulenin on A23187-stimulated exocytosis is of 
note since the calcium ionophore largely bypasses the signaling steps required for 
agonist-induced platelet activation. The fact that cerulenin inhibits A23187-induced 
platelet secretion strongly suggests that acylation is directly important for t-SNARE 
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function in membrane fusion, and not solely required for upstream signaling processes 
as is implied by Sim et al. (102). 
The acyl-protein thioesterase (APT) inhibitor, palmostatin B inhibits deacylation. 
Given that our data with cerulenin-treatment showed that acylation is important for 
platelet function, we sought to determine if deacylation might contribute to the 
process. To study the cycle of SNAP-23 and syntaxin-11 acylation, palmostatin B 
and/or cerulenin were added to washed platelets at different stages of the incubation 
period. First, acylation was measured from immunoprecipitated t-SNARE proteins 
using the IP-ABE assay. Unlike what was seen with cerulenin-treatment, palmostatin 
B enhanced acylation on syntaxin-11 and SNAP-23 compared to vehicle-treated 
platelets (Figure 4-21). Palmostatin B, unlike cerulenin, appeared to have no effect on 
platelet secretion in response to thrombin or A23187 Figure 4-20. These data 
suggested that there was a thioesterase-mediated removal of the t-SNARE acyl groups 
and that these groups must be replaced to retain platelet function. To address this point, 
palmostatin B and cerulenin were added sequentially in different orders. While 
pretreatment with cerulenin prior to palmostatin B inhibited platelets, the converse 
(palmostatin B treatment first) restored platelet activity. These data would suggest a 
constant cycle to thioesterase mediated acyl group removal that is counteracted by 
PAT activity. It is this reacylation that appears to be important for maintaining 
functionally active platelets. 
Acylation is not the Only Factor Affecting Membrane Association: Acylation 
provides t-SNAREs with lipid anchors, assisting their membrane association; however 
72 
 
there could be other factors that mediate membrane association. To address this point 
we examined protein distributions after chemical deacylation with HA. In Figure 4-24, 
HA treatment released very little of the two t-SNAREs from membranes After 
chemical deacylation HA, syntaxin-11 and SNAP-23 still stayed in the detergent 
phase of the Triton X-114 partitioning, indicating that their hydrophobicity had not 
changed compared to control group (no HA treatment; Figure 4-23). In Figure 4-25, 
syntaxin-11 and SNAP-23 were still present in lipid rafts after cerulenin treatment. 
Overall, these results indicate that deacylation may not be sufficient to completely 
release t-SNAREs from membranes. Other factors, such as protein-protein interaction, 
or some unidentified modifications of these two proteins may affect their membrane 
association. Consistently, in PC12 cells, acylation is essential for SNAP-25 initial 
targeting to membrane, but its membrane association can be maintained by 
protein-protein interactions after deacylations (117). 
Discussion 
From our data, the S-acylation/deacylation cycle in platelets appears to be 
dynamic and very important for platelet exocytosis. Thioesterases are actively 
removing the acyl groups on the two t-SNAREs and PATs appear to be replacing 
them. Hence we observed a time-dependent incorporation of [
3
H]-palmitic acid into 
the two proteins. This incorporation was not altered by platelet activation state since 
there was no significant increase in [
3
H]-palmitic acid incorporation into syntaxin-11 
and SNAP-23 upon platelet activation by thrombin. There was minimal enhancement 
of incorporation into total lysates. Previously, [
3
H]-palmitic acid incorporation into 
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two unidentified, 38 kDa and 23 kDa proteins was reported in platelets and the 
incorporation was enhanced upon activation with thrombin within. Incorporation 
reached a plateau after 15 min and other agonists, i.e., collagen and A23187, had no 
effect (189). In experiments reported here the incubation times were longer i.e., 1-2 hr, 
and there was a time-dependence despite being longer than the originally reported 
incorporation plateau time (15 min). Syntaxin-11 and SNAP-23 are less abundant than 
the originally detected 38 kDa and 23 kDa proteins; despite the coincident molecular 
weights, immuno-depletion studies suggested neither t-SNARE was one of these 
original two acylated proteins.  
2-Bromopalmitate (2BP) was used as another acylation inhibitor in β cells, 
platelets as well as in other cells (159,190). However, in our experience when washed 
platelets or PRP were treated with 10μM-100μM 2BP, the platelets appear to be 
solubilized or destroyed and thus it was not used in our studies. Since 2BP contains a 
long chain fatty acid, perhaps it acts as a detergent but this was not addressed 
experimentally.  
The fusogenic activity of the SNAREs could depend on the number of acyl 
groups attached to the cysteine-rich regions, this has been seen in PC12 cells with 
SNAP-23 (119). Even after replacing the TMDs of Syntaxin-1 and VAMP-2, with the 
cysteine-rich region of syntaxin-19, the two SNAREs were able to efficiently mediate 
membrane fusion of synaptic vesicle (191). Replacing the Q-SNARE, Nyv1p’s TMD 
with a lipid anchor did not affect its fusogenicity (192). Like syntaxin-19, SNAP-23 
and syntaxin-11 both possess cysteine-rich regions instead of TMD and as the extent 
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of acylation is decreased membrane fusion is affected. From our acylation site 
analysis (Figure 4-13), it appears that all the cysteine residues in the cysteine-rich 
regions of both SNAP-23 and Syntaxin-11can be modified by IAA after HA treatment 
suggesting that all the cysteines can be acylated for at least some population of the 
SNAREs. We were unable to detect partially modified peptides that contained both 
NEM and IAA modified peptides. We did however detect cysteines that were most 
likely involved in disulfide bonds or as free sulfhydryls. These were not in cysteine 
rich regions. 
SNAP-23 and syntaxin-11 are still localized to lipid rafts, even when the 
platelets are pre-treated with cerulenin (Figure 4-25). At this stage, we cannot 
evaluate the degree to which the SNAREs are deacylated as a result of the cerulenin 
treatment so it is difficult to assess how important acylation is to raft association. The 
raft association would argue that the t-SNAREs still retain some of their acyl groups. 
Protein-protein interaction may also keep them associated with the membranes and 
lipid rafts. Acylation is recognized as a modification that promotes association with 
lipid rafts (90,120). It is interesting to note that in resting platelets there is only partial 
localization of syntaxin-11 and SNAP-23 to the lipid rafts of platelets. This 
distribution changes upon platelet activation where even more of the SNAREs are 
mobilized to lipid rafts. While acylation assists in raft association, we only see a 
minor change in the extent of SNARE acylation upon activation, suggesting that some 
other factor(s) might affect raft association. Perhaps raft association is controlled by 
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both acylation and some protein-protein interaction that is responsive to platelet 
stimulation. Further experiments will be required to address this point. 
Overall, protein acylation appears to be important for SNARE-mediated 
exocytosis from activated platelets. It may not be the determining factor for their 
membrane association but it could affect partitioning into rafts and thus SNARE 
localization. Additionally, since the acyl groups appear to turnover rapidly, the degree 
and composition of the acyl groups may be highly sensitive to the Acyl-CoAs present 
in platelets, thus accounting for the increase platelet reactivity seen in patients with 
dyslipidemia. These are future questions that are derived for the experiments in this 
chapter. 
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Figure 4-1 Syntaxin-11 and SNAP-23 are Associated with Platelet Membranes  
Total lysates were prepared from washed platelets by 5 freeze-thaw cycles and were 
subjected to ultracentrifugation at 100,000 × g for 1 hr at 4°C to separate plasma 
membrane and cytosol fractions. The membrane fractions treated with 1% Triton 
X-100 for Triton X-100-soluble (STX) and insoluble fractions (ITX). Equivalent 
amounts of fractions were analyzed by SDS-PAGE and probed by western blotting 
with the indicated antibodies. Blots shown are representative of three independent 
experiments. 
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Figure 4-2 Syntaxin-11 and SNAP-23 Are Present in Lipid Rafts Increases Upon 
Platelet Activation 
A). Resting (R) or thrombin-stimulated (S) platelets were lysed in 2× raft lysis buffer, 
then mixed 1;1 with 1.5 mL 80% sucrose in MBS (final sucrose concentration is 40%) 
and layered into ultracentrifuge tubes. 6 mL 30% sucrose were layered on 40% 
mixture, and finally 2 mL 5% sucrose were layered on the top. The samples were 
subjected to ultracentrifugation at 200,000 × g for 18 hr at 4°C. B). The gradients 
were fractionated and probed for the indicated proteins by western blotting. Top: Blots 
shown are representative of three independent experiments. Bottom: Quantifications 
of the specific proteins in each fraction were shown.  
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Figure 4-3 Cholesterol Depletion Affects t-SNARE Localization 
Washed platelets (1 × 10
9
/mL) were treated with 10 mM Methyl-β-cyclodextrin 
(MβCD) for 15 min at 37°C. Untreated (R) or MβCD-treated platelets were lysed in 
2× raft lysis buffer and layered into ultracentrifuge tubes and c The samples were 
subjected to ultracentrifugation at 200,000 × g for 18 hr. The gradients were 
fractionated and probed for the indicated proteins by western blotting. Blots shown 
are representative of three independent experiments. Quantifications of specific 
proteins in each fraction are shown.  
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Figure 4-4 Cholesterol Depletion Affects Platelet Secretion and Aggregation 
Washed platelets (4 × 10
8
/mL) were treated with or without10 mM 
Methyl-β-cyclodextrin (MβCD) for 15 min at 37°C. Then platelets were stimulated 
with 4μM A23187 and 0.1U/mL thrombin. ATP release and aggregation were 
recorded by lumi-aggregometry. Data shown are representative of at least three 
experiments. 
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Figure 4-5 Methyl-β-cyclodextrin Treatment Depletes Platelet Cholesterol  
The lipids from washed human platelet lipids were extracted with 200 μL chloroform: 
isopropanol: NP-40 (7:11:0.1) and centrifuged to remove non-lipid fraction. Platelet 
cholesterol was determined using a cholesterol oxidase assay (Amplex Red 
Cholesterol Assay Kit, Invitrogen, Life technologies, Grand Island, NY) and 
converted into µg/10
9
 platelets. Data were expressed as mean ± standard deviation. 
N=9 for each group, ****p<0.0001, using an unpaired student’s t-test.  
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Figure 4-6 Aggregation, ATP Release and Cholesterol Levels are Increased in 
ApoE
-/- 
Platelets 
A). Washed platelets (4 × 10
8
/mL) from WT and ApoE
-/-
 mice were stimulated with 
10 µM A23187. ATP release was monitored in a Lumi-Aggregometer. (Tracings are 
representative of triplicate). B). Platelet lipids were extracted with 200 μL chloroform: 
isopropanol: NP-40 (7:11:0.1) and centrifuged to remove non-lipid fraction. Platelet 
cholesterol was determined using a cholesterol oxidase assay (Amplex Red 
Cholesterol Assay Kit, Invitrogen, Life technologies, Grand Island, NY) and 
converted into µg/10
9
 platelets. Data are expressed as mean ± standard deviation. N=9 
for each group, ****p<0.0001, using an unpaired student’s t-test.  
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Figure 4-7 Syntaxin-11 and SNAP-23 are Acylated in Platelets.  
Washed platelets (1 × 10
9
/mL) were lysed with ice cold 1× Lysis Buffer containing 50 
mM NEM at 4°C for 60 min. Anti-syntaxin-11 and anti-SNAP-23 Abs were added 
into lysates and incubated at 4°C. After overnight-incubation, IP samples were treated 
with 0.1 M HA for 30 min prior to biotinylation with BMCC-biotin. The omission of 
HA was used as a negative control. The samples were separated by SDS-PAGE and 
probed for anti-syntaxin-11 and anti-SNAP-23 antibodies by western blotting and for 
biotinylation with streptavidin-alkaline phosphatase conjugate. Blots shown are 
representative of three independent experiments. 
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Figure 4-8 [
3
H]-Palmitic Acid Incorporation into Platelet Syntaxin-11 and 
SNAP-23 
A). Human washed platelets were incubated with [
3
H]-palmitic acid for 2 hr, platelet 
lysates were subjected to IP with anti-SNAP-23 and anti-syntaxin-11 Abs and the 
proteins were visualized as above; B). and C). 2.5% HA were incubated with 
[
3
H]-palmitate-labeled immunoprecipitated samples. HA treated immunoprecipitated 
proteins were separated by SDS-PAGE and visualized by autofluorography. The 
aliquots of HA treated samples were also probed by western blotting with 
anti-syntaxin-11 and anti-SNAP-23 Abs. Blots or data shown are representative of at 
least two independent experiments. 
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Figure 4-9 MS/MS of the Acylated Peptide from Syntaxin-11: 
TLC
279
C
280
FC
282
C
283
PC
285
LK 
Mass spectrums were shown with IAA modified for detecting acylation sites in 
acylated peptide TLC
279
C
280
FC
282
C
283
PC
285
LK of syntaxin-11. Modification sites 
were identified based on MS/MS fragmentation patterns. For clarity, only y and b ions 
are shown. The y ions are labeled in blue, the b ions in red. 
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Figure 4-10 MS/MS of the Acylated Peptide from Syntaxin-11: 
KAVQYEEKNPC
275
R 
Mass spectrums were shown with IAA modified for detecting acylation sites in 
acylated peptide KAVQYEEKNPC
275
R of syntaxin-11. Modification sites were 
identified based on MS/MS fragmentation patterns. For clarity, only y and b ions are 
shown. The y ions are labeled in blue, the b ions in red. 
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Figure 4-11 MS/MS of the NEM Modified Peptide from Syntaxin-11: 
GEVIHC
102
K 
Mass spectrums were shown with NEM modified for detecting acylation sites in 
peptide GEVIHC
102
K of syntaxin-11. Modification sites were identified based on 
MS/MS fragmentation patterns. For clarity, only y and b ions are shown. The y ions 
are labeled in blue, the b ions in red. 
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Figure 4-12 MS/MS of the NEM Modified Peptide from Syntaxin-11: 
QRDNC
157
KIR 
Mass spectrums were shown with NEM modified for detecting acylation sites in 
peptide QRDNC
157
KIR of syntaxin-11. Modification sites were identified based on 
MS/MS fragmentation patterns. For clarity, only y and b ions are shown. The y ions 
are labeled in blue, the b ions in red. 
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Figure 4-13 MS/MS of the Acylated Peptide from SNAP-23: 
C
79
C
80
GLC
83
VC
85
PC
87
NR 
Mass spectrums were shown with IAA modified for detecting acylation sites in 
acylated peptide C
79
C
80
GLC
83
VC
85
PC
87
NR of SNAP-23. Modification sites were 
identified based on MS/MS fragmentation patterns. For clarity, only y and b ions are 
shown. The y ions are labeled in blue, the b ions in red. 
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Figure 4-14 MS/MS of the Acylated Peptide from SNAP-23: 
TTWGDGGENSPC
112
NVVSK 
Mass spectrums were shown with IAA modified for detecting acylation sites in 
acylated peptide TTWGDGGENSPC
112
NVVSK of SNAP-23. Modification sites were 
identified based on MS/MS fragmentation patterns. For clarity, only y and b ions are 
shown. The y ions are labeled in blue, the b ions in red. 
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Figure 4-15 Dynamic Acylation of Syntaxin-11 and SNAP-23 in Platelets 
Platelets were incubated with [
3
H]-palmitic acid in the presence or absence of 500 µM 
cerulenin. Some were stimulated with thrombin and others were treated with PGI2. 
Lysates were prepared for IP with anti-syntaxin-11 Ab (A) or anti-SNAP-23 Ab (B). 
Total protein (top) or immunoprecipitated proteins were separated by SDS-PAGE and 
visualized by autofluorography. Total protein and immunoprecipitated samples were 
also probed by western blotting with anti-syntaxin-11 Ab (middle) and anti-SNAP-23 
Ab (bottom). Blots or data shown are representative of at least two independent 
experiments. 
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Figure 4-16 Cerulenin Inhibits Acylation of Platelet t-SNAREs 
Platelets were treated with 500µM cerulenin (Ceru) for 2 hr. IP-ABE assay was 
performed for acylation detection after pre-incubation with cerulenin. The ratio of 
streptavidin-syntaxin11/total syntaxin-11 (A) quantification and 
streptavidin-SNAP-23/total SNAP-23 (B) quantification are shown. Blots or data 
shown are representative of at least two independent experiments. 
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Figure 4-17 Cerulenin Inhibits ATP Release and Platelet Aggregation 
Washed platelet suspensions (4 × 10
8
/mL, 500 μL) were pre-treated with 56 µM, 167 
µM and 500 µM cerulenin, respectively, for 2 hr at 37°C. Aggregation traces and ATP 
release were monitored. Tracings shown are representative of at least three separate 
experiments.  
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Figure 4-18 Time Dependent Inhibition of ATP Release after Cerulenin 
Treatment 
Platelets were treated with cerulenin for the indicated times and aggregation in 
response to 0.1U/mL thrombin was measured by light transmission aggregometry. 
Data shown are representative of at least two independent experiments. 
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Figure 4-19 Cerulenin-Treatment Affects P-Selectin Exposure 
Washed human platelets (1 × 10
8
/mL) were treated with cerulenin (0, 56, 167, and 
500μM) at 37°C for 2 hr. Thrombin (0.1 U/mL) or A23187 (4 μM) were used as 
agonists to stimulate platelets for 3 min. FITC-conjugated anti-P-selectin was added 
for 10 min. Fluorescent intensities were measured by FACS. The data were graphed 
using Geometric Mean Fluorescence Intensity (GMFI): P-selectin. Quantification of 
the P-selectin exposure is shown. Data shown are representative of at least three 
experiments. 
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Figure 4-20 Palmostatin B Counteracts the Inhibitory Effects of Cerulenin 
Washed platelet (4 × 10
8
/mL) were treated with cerulenin (Ceru) or palmostatin B 
(Palmo B) alone ; or treated with both drugs sequentially: cerulenin or palmostatin B 
treated for 1 hr, the other drug treated for additional 1 hr. Buffer control group was 
also set up. Platelets were stimulated with agonists A23187 and Thrombin. ATP 
release was monitored. Quantifications of the ATP release in treated groups is shown 
(n=3). Data shown are representative of at least two experiments. 
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Figure 4-21 Acylation Accumulated in Palmostatin B-Treated Platelets 
Washed platelets (1 × 10
9
) were incubated in presence or absence of cerulenin (Ceru) 
and palmostatin B (Palmo B), and then lysed by lysis buffer. IP-ABE assay were used 
to detect acylation of syntaxin-11 and SNAP-23 after drug treatment. The ratio of 
streptavidin-syntaxin11/total syntaxin-11 (A) quantification and 
streptavidin-SNAP-23/total SNAP-23 (B) quantification are shown. Data shown are 
representative of at least two experiments. 
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Figure 4-22 Intracellular Ca
2+
 Measurement in Cerulenin Treated Platelets 
Intraplatelet calcium was measured using Fura-2-acetoxymethyl ester (Fura-2AM). 
Washed platelets (4 × 10
8
/mL) in HEPES-Tyrode’s buffer (pH7.4) were incubated in 
presence or absence of cerulenin at 37 °C for 1 hr. Then 1 µM Fura-2AM (Invitrogen) 
was added into platelets at 37 °C for 1 hr. After incubation, the Fura-2 loaded platelets 
were resuspended in HEPES-Tyrode’s buffer (pH7.4). The platelet concentration was 
adjusted to 2 × 10
8
/mL. 0.7 mM CaCl2 and 750 µl platelets were added to siliconized 
cuvettes and stimulated with 0.1 U/mL thrombin and constant stirring. Fluorescence 
was analyzed by excitation at 340 nm and 380 nm, and emission was measured at 509 
nm using a model LS55 Luminescence Spectrometer (Perkin-Elmer Cetus). The ratio 
of emissions was calculated simultaneously A) vehicle group, B) 56 μM cerulenin, C) 
167 μM cerulenin, D) 500 μM cerulenin group. Data shown are representative of at 
least three experiments. 
  
101 
 
 
 
Figure 4-23 t-SNAREs Partition into Triton-114 Phase after HA Treatment 
Platelet plasma membrane was solubilized in 2% Triton X-114 and treated with or 
without 0.3 M HA at 4°C for 1 hr. After incubation, the samples were subjected to 
centrifugation and fractions were separated and collected. Triton X-114 fraction 
(detergent) and non-Triton X-114 fraction (aqueous) was subjected to western blot 
with anti-syntaxin-11, anti-SNAP-23, anti-VAMP-8, and anti-syntaxin-4 antibodies. 
Data shown are representative of at least two experiments. 
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Figure 4-24 t-SNAREs are Not Released from Plasma Membranes by HA 
Treatment 
Human plasma membrane were isolated and treated with or without 0.7M HA (pH 7.4) 
in buffer containing 1M NaCl for 30 min with rotating at 37 °C. After incubation, 
ultracentrifuge was performed and supernatant and pellet were kept and subjected to 
western blotting. Blots are representative of 3 different experiments. 
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Figure 4-25 t-SNAREs are Present in Lipid Rafts Even after Cerulenin 
Treatment 
Vehicle (R) or cerulenin treated (C) platelets were lysed in 2× raft lysis buffer and 
layered into ultracentrifuge tubes. The samples were subjected to ultracentrifugation 
at 200,000 × g for 18 hr at 4°C. The gradients were fractionated and probed for the 
indicated proteins by western blotting. Blots shown are representative of at least three 
experiments. Quantification of the specific proteins in each fraction is shown.  
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Chapter Five: Conclusions and Future Directions 
Conclusions:  
In this dissertation, I have studied post-translational modifications (PTM) in two 
platelet t-SNAREs to determine their dynamics and how they affect platelet function. 
In Chapter 3, using an in vitro, proteoliposome fusion assay, I demonstrated that 
purified IκB Kinase (IKK) phosphorylated SNAP-23 and this modification increased 
the initial rates of SNARE-mediated liposome fusion. Both phosphorylation and 
fusion enhancement required IKK activity. Mutants, containing phosphomimetics, 
Asp95 or Glu95, also showed enhanced initial fusion rates. In Chapter 4, I examined 
how the S-acylation of SNAP-23 and syntaxin-11 to understand how acylation may 
regulate the protein function and thus platelet exocytosis. Using metabolic labeling 
and hydroxylamine treatment, I showed that both contain thioester-linked acyl groups 
and that acylation dynamically turns over in platelets, despite their apparent lack of 
protein synthesis. Cerulenin pretreatment inhibited t-SNARE acylation and platelet 
function in a dose- and time-dependent manner while palmostatin B had no effect. 
Interestingly, pretreatment with palmostatin B blocked the inhibitory effects of 
cerulenin suggesting that maintaining the acylation state of platelet proteins is 
important for function. In summary, my work has shown that phosphorylation and 
acylation affect t-SNARE function and platelet secretion. 
SNAP-23 Phosphorylation in Platelets 
The Effect of SNAP-23 Phosphorylation on SNARE Complexes: In Chapter 3, I 
present data demonstrating SNAP-23 phosphorylation at Ser95 enhances membrane 
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fusion but is not required. Consistently, when Ser95 was changed to Asp or Glu, the 
mutant SNAP-23s also enhance membrane fusion in vitro. These data argue that 
SNAP-23 phosphorylation somehow affects SNARE function by: 1) Promoting 
SNARE complex formation; 2) Stabilizing SNARE complexes: and/or 3) Affecting 
the spatial distribution of SNAREs. Given the inherent stability of SNARE complexes, 
as evidenced by their high melting points (193), it seems unlikely that stabilizing a 
SNARE complex, once formed, is the major role for phosphorylation. Our previous 
results support a role of SNAP-23 phosphorylation in SNARE complex formation. 
Functionally relevant SNARE complexes (SNAP-23/syntaxin-11/VAMP-8 or 
SNAP-23/syntaxin-2/VAMP-8) formed in activated platelets and could be detected by 
co-immunoprecipitation and western blotting (80). This corresponded to SNAP-23 
phosphorylation; the SNAP-23 in the SNARE complex was phosphorylated on Ser95. 
Inhibition of or genetic deletion of IKKβ not only blocked platelet exocytosis and 
SNAP-23 phosphorylation, but also affected SNARE complex formation; no SNARE 
complexes were detected. While these data are suggestive of a mechanism, our 
understanding is incomplete. We must determine which form of SNAP-23 is the 
relevant IKKβ substrate in order to assemble the sequence of events and understand 
the molecular roles of SNAP-23 phosphorylation. Several forms of SNAP-23, in 
different protein complexes (SNAP-23, SNAP-23/syntaxin, 
SNAP-23/syntaxin/VAMP-8), are possible and each should be tested. If monomeric or 
heterodimeric SNAP-23 are preferred IKKβ substrates, then phosphorylation could 
drive association of the t-SNAREs with each other or with the v-SNAREs, or both. 
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This remains to be directly addressed experimentally, though the data in Chapter 3 
does show that t-SNARE heterodimers can be phosphorylated in vitro. 
In RBL-2H3, SNAP-23 associates with syntaxin-4/VAMP-2 and is 
phosphorylated upon stimulation (83). In this system, SNAP-23 is thought to recruit 
syntaxin-4 and VAMP-2 to lipid rafts and this recruitment correlates with SNAP-23 
phosphorylation and the formation of phopho-SNAP-23/syntaxin-4/VAMP-2 
complexes. These data suggest that SNAP-23 phosphorylation promotes SNARE 
complex formation in mast cells, as postulated in platelets and may also promote 
SNARE partitioning into lipid rafts. Given that SNAP-23 and syntaxin-11 are 
associated with lipids rafts (Figure 4-2), it would seem that SNAP-23 phosphorylation 
could have a similar effect in platelets as it does in mast cells. While this was 
examined in platelets, no conclusive data was generated and thus further examination 
of the relationship between phosphorylation, acylation, and raft association is 
warranted based on the data presented in this dissertation and that in the literature 
(83). 
IKK Inhibitors and their Clinical Use: The IKK complex (IKKα/β/γ) is a 
ubiquitous regulator of NF-κB-based signaling in many cellular proceses. It has been 
shown to be involved in immune regulation, tumor growth/progression and several 
inflammatory diseases (194). IKK inhibitors do block SNAP-23 phosphorylation and 
IKK-enhanced membrane fusion (Figure 3-2 and Figure 3-3). They also block platelet 
exocytosis (80). IKK inhibitors, BMS 345541 and TPCA-1, used in this dissertation 
have not been widely used in clinical trials though there is some proof of their efficacy. 
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BMS 345541 promotes apoptosis in melanoma cells (195,196). TPCA-1 reduces 
tumor progression and increases the median survival time in a mouse tumor model 
(194). TPCA-1 also blocks the inflammation associated with arthritis and asthma. It 
decreases T cell proliferation and attenuates collagen-induced arthritis (197) as well as 
the inflammation in human smooth muscle airways and in a rat asthma model (198). 
There are several IKKβ inhibitors that have been developed in the recent years but 
few has been tested in pre-clinical trials (199-201). Our results show that IKKβ 
inhibition does block platelet secretion and significantly prolongs bleeding times in 
mice (80). The data in this dissertation further elucidates the mechanism by which 
IKKβ, through phosphorylation of SNAP-23, can regulate the membrane fusion 
needed for granule cargo release. Based on our data, IKKβ may be a viable 
therapeutic target for cardiovascular disease, and thus IKKβ inhibitors could be 
repurposed for cardiovascular disease treatment. Though this remains to be validated, 
it seems that bleeding could be a side-effect of IKKβ inhibition that will require 
monitoring in future clinical trials of the various IKKβ inhibitors that are being 
developed. 
t-SNARE Acylation in Platelets 
Enzymology of Platelet Acylation: Acylation/deacylation is dynamic and reversible, 
being regulated by synthetic PATs, substrate availability (i.e., acyl-CoAs), and 
degradative palmitoyl thioesterases (Figure 5-1). Typical PATs contain a conserved 
cysteine-rich domain and an Asp-His-His-Cys (DHHC) motif (131-133) which serve 
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as family signatures. There are 25 ZDHHC proteins found in humans (125,135). PAT 
activities depend on these DHHC domains, as mutations of the cysteine abolish 
auto-acylation and acyl-transferase activity (136). Nine of the PATs are associated 
with human disease. The majority of PATs are associated with the endoplasmic 
reticulum (ER) or Golgi; however, a few localize to the plasma membrane (138). 
While it has been demonstrated that neuronal PATs exhibit distinct protein substrate 
specificity (139), the fact that there are several hundred acylated proteins in diverse 
cell types and tissues (112,202-205) suggests that at least some PATs must act on 
several substrates. Some PATs appear redundant and can compensate for each other. 
Thus several PATs could work together to control acylation of a specific protein. For 
instance, in neuronal cells, HIP14 (ZDHHC17) regulates acylation of SNAP-25 
(131,140). However, coexpression of ZDHHC2 and SNAP-25 leads to enhanced 
palmitoylation of SNAP-25 in HEK293T (human embryonic kidney 293T) cells (141). 
When ZDHHC3, 7, 17 were co-transfected into HEK293T cells, they also increased 
palmitoylation of SNAP-25 (132). Acyl-CoAs might also be differentially used by 
PATs. Jennings et al., found that ZDHHC2 and ZDHHC3 display different acyl-CoA 
specificities (206). ZDHHC2 used various acyl-coA species (C14,C16, C18, C20 and 
some unsaturated acyl-CoA) with almost equal efficacies; whereas ZDHHC3 displays 
much lower efficiencies with acyl-CoAs bearing longer carbon chains (C>16). The 
mechanism by which ZDHHCs recognize the different carbon lengths of the 
acyl-CoAs remain unknown. Overall, ZDHHCs may share some protein substrate 
specificity; but, these data strongly suggest that availability of enzymes as well as the 
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substrates (i.e., acyl-CoA) may be very important in affecting the dynamics and extent 
to which a specific protein is acylated in a given cell type. At present, at least 13 
ZDHHC enzymes or their mRNAs have been identified in platelets (Chapter 3, Table 
1-1). 
Currently, three dimensional structures of ZDHHC proteins are not available, 
so structure-based drug design is more difficult. Regulating acylation of proteins with 
the PAT inhibitors such as cerulenin or 2BP is perhaps not optimal due to their 
non-specificity. Many proteins are acylated and it is essential for protein function and 
cell growth. Non-selective acylation inhibitors may ultimately be quite cytotoxic. 
Blocking the activity of a specific ZDHHC protein may be less toxic and may also 
focus the study of acylation of certain proteins. Knockout mouse models can be used 
to determine which enzyme is responsible for regulating SNAP-23 and syntaxin-11 
acylation. This would be helpful if specific enzymes are responsible for regulating 
acylation of t-SNARE and thus for platelet. However, given the potential redundancy 
of the various PATs and the fact that many have been detected in platelets directed 
PAT inhibition may not be a viable approach. Therapeutic titrations may however be a 
strategy for using PAT inhibitors as anti-thrombotics. Overall, current PAT inhibitors, 
e.g., cerulenin and 2BP, are non-selective; they can block all of PATs. Identifying 
which PATs are responsible for regulating SNAP-23 and syntaxin-11 in platelets, it 
may provide novel targets to control the acylation of SNAP-23 and syntaxin-11 
specifically but this will required more work (see discussion below). 
Compared to the large number of acyltransferases-ZDHHC proteins, only 4 
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thioesterases have been identified in platelets: APT1, APT2, PPT1, and PPT2 
(102,127,128). PPT1 and PPT2 are found in lysosomes and are important for 
degradation of acylated proteins (128). APT1 and APT2 are cytoplasmic enzymes and 
are thought to deacylate proteins non-specifically (167). From my work, palmostatin 
B inhibits the deacylation of both SNAP-23 and syntaxin-11 and thus counteracts the 
effects of cerulenin on platelet secretion We interpret this as proof that cycling of 
acylation occurs in platelets and is important for platelet function. This might suggest 
that palmostatin B could be repurposed to maintain platelet activity during storage; 
assuming that during storage, platelet acyl-CoA levels could decrease (or change 
composition) due to increased use to maintain platelet energetics or membrane 
integrity. The result could be a loss of t-SNARE acylation and thus a loss of secretory 
competency. Palmostatin B could delay the deacylation process and thus retard the 
loss of secretory competency. Future studies of stored platelets and the extent on 
t-SNARE acylation during storage will be required to address the feasibility of this 
approach.  
Pharmacologic Acylation Effectors: PAT inhibitors, e.g., cerulenin and 2BP, are 
widely used for inhibiting acylation. They affect acylation of a diverse set of proteins, 
e.g., H-Ras and PSD95 (207,208). Both cerulenin and 2BP can non-selectively and 
irreversibly inhibit the activity of PATs. 2BP resembles palmitate (Figure 1-3) and was 
used as an acylation inhibitor via alkylating PATs. Because PAT inhibitors disrupt 
palmitoylation of diverse proteins including Ras, they can potentiality regulate cell 
proliferation, neural development and thus have been used trial for cancer treatment. 
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2BP impairs neural stem cell proliferation and induces cell apoptosis (209). 2BP 
inhibits the acylation of CD63 in platelets (159); however, in our experiments, 2BP 
(10μM-100μM) appeared to solubilize platelets, thus destroying them. Similarly, 
Jurkat T cells, are more sensitive to 2BP treatment and could not tolerate treatment 
overnight (160). From its chemical structure, 2BP contains a long chain fatty acid, 
which may act as a detergent to destabilize platelet membranes. Instead of 2BP, 
cerulenin was used in this dissertation to study acylation in platelets. Cerulenin is an 
antibiotic identified as a fatty acid synthetase inhibitor. Kawaguchi et al. showed that 
cerulenin reacts with the SH-group in the synthetase active site and thus inhibits fatty 
acid biosynthesis (210). Cerulenin has also been widely used as an acylation inhibitor 
via alkylating PATs (157). Similar to the results reported in this dissertation, it 
inhibited platelet secretion, aggregation, accumulation and delayed thrombi formation 
in vivo (211), indicating its potential as anti-thrombotic drug (102). From our results, 
platelet secretion was affected and inhibited by cerulenin through deacylation of 
SNAP-23 and syntaxin-11, which may be used in anti-thrombi formation and as a 
potential drug target. The mechanism of cerulenin as an acylation inhibitor is not well 
understood. Several studies showed that cerulenin can decrease the number of free 
thiols of either PAT or the substrate proteins (157,212). Besides 2BP and cerulenin, 
tunicamycin has been used to inhibit acylation, though it is also widely used to inhibit 
N-linked glycosylation (160). Because of its side effects, we did not use tunicamycin. 
Both 2BP and cerulenin also inhibit other enzymes involved in lipid metabolism. A 
novel PAT inhibitor, 2-(2-hydroxy-5-nitro-benzylidene) -benzo[b]thiophen-3-one 
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(Compound V), was tested and specifically inhibited all PATs reversibly by inhibiting 
autoacylation which is a different mechanism from either 2BP or cerulenin, which are 
irreversible inhibitors (207). Overall, most current acylation inhibitors are 
non-selectively and irreversibly inhibit the activity of PATs except Compound V, 
which is not commercially available. In the dissertation, cerulenin and 2BP have been 
chosen as “the best” acylation inhibitors available.  
Palmostatin B inhibits APT and regulates protein deacylation, but not 
acylation. H- and N-Ras deacylation was inhibited by palmostatin B, thus affecting its 
distribution back to Golgi and most of Ras distribute in plasma membrane (213). 
Oncogenic-Ras-transformed MDCK-f3 cells reduced cell-cell contact and became 
multi-layers, thus oncogenic Ras activity contributes to cancer progression. 
Palmostatin B prevents the oncogenic transformation and induces a partial phenotypic 
reversion (214). In platelets, palmostatin B not only inhibits deacylation of t-SNAREs, 
syntaxin-11 and SNAP-23, but also counteract the effect of cerulenin (Figure 4-20). 
Due to non-selectivity, palmostatin B may be used for disrupting the cycle of 
acylation/deacylation. It may keep acylated protein in steady states and may be used 
to control platelet function. Neither PAT inhibitors nor palmostatin B are selective, 
which will be a challenge in clinical trials. How to improve or enhance the drug 
selectivity is worthy of future study. Either new specific drugs or drug delivery 
systems may solve the non-selective issues.  
Effects of Acylation on Platelet SNAREs: Conventional SNARE proteins contain 
TMDs, which have been shown to be important in mediating membrane fusion (215). 
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It is unclear whether all lipid anchors can provide sufficient hydrophobicity to the 
SNAREs to mimic the TMDs. Acylation can provide the hydrophobicity needed for 
inserting into lipid bilayers, which helps SNAREs without TMD attach to membranes 
but what is sufficient for driving membrane fusion. Is the extent of acylation or the 
composition (i.e., length and desaturation) of the fatty acids important for fusogenicity? 
SNARE proteins with lipid anchors can mediate membrane fusion in in vitro assays 
under specific conditions (216). Multiple lipid moieties can enable lipid-anchored 
SNARE to drive membrane fusion (217). Synaptobrevin-2 (VAMP-2), lacking a TMD, 
attached to proteoliposomes through one or two acylation sites is not sufficient for in 
vitro membrane fusion (218). The R-SNARE, Nyv1p, with an engineered lipid anchor 
that spanned half the lipid bilayer, also could not mediate membrane fusion in lipid 
mixing assay. However, addition of accessory proteins, such as HOPS, Sec17p, and 
Sec18p, did enable the lipid-anchored Nyv1p to drive membrane fusion (192). Studies 
by McNew et al. suggested that longer more hydrophobic lipid moieties could 
promote membrane fusion (219). TMDs were replaced by prenyl groups of different 
lengths and while C15 and C20 groups were insufficient for fusion, C55 groups could 
promote fusion in vitro. Overall, the length of lipid anchors, the number of 
modification sites, and the accessory proteins appear to affect efficiency of membrane 
fusion by SNAREs lacking TMDs. In my dissertation, syntaxin-11 and SNAP-23 lose 
their ability to drive membrane fusion, when platelets are treated with acylation 
inhibitors, but do not appear to lose their associations with membranes and lipid rafts. 
This suggests two related roles for SNARE acylation in platelets, dependent on the 
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extent of acylation. Membrane association and lipid raft distribution requires a lower 
level of acylation while membrane fusion requires a greater degree of acylation. One 
ramification of this conclusion is that as acylation decreases, the deacylated SNAREs 
could become inactive decoys for SNARE complex formation and, in fact, inhibit 
membrane fusion. Thus deacylation could negatively affect membrane fusion by 
reducing fusogenicity and by producing an inhibitory SNARE that diverts SNARE 
complex formation from fusogenic SNAREs. 
Acylation Promotes SNARE Localization to Lipid Rafts: Lipid rafts are 
specialized cholesterol- and sphingolipid-enriched domains of plasma membrane. 
They are associated with several cellular functions including signaling and have 
recently been proposed to be important for efficient exocytosis (220). In my studies, 
syntaxin-11 and SNAP-23 are both enriched in lipid rafts upon activation. This is also 
seen in other cells such as NK cells and mast cells (80,99,121). Since SNARE 
complexes (syntaxin-11/SNAP-23/VAMP-8) formation increases upon activation (80) 
and VAMP-8 is enriched in rafts upon platelet activation, it is possible that SNARE 
complexes form in the rafts in an activation-dependent manner (Figure 4-2). Upon 
cholesterol depletion with MβCD, fewer SNAREs were present in lipid rafts and there 
was a decrease in stimulation-dependent release of ATP and less aggregation (Figure 
4-4). Consistently in mast cells, ternary SNARE complexes 
(SNAP-23/syntaxin-4/VAMP-2) are redistributed into lipid rafts during exocytosis, 
and cholesterol-enriched, lipid rafts are important for exocytosis in mast cells (90). In 
PC12 cells, SNAP-23 contains 5 cysteines in its central cysteine-rich region, but it has 
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a three-fold higher affinity for lipid rafts than that of SNAP-25, which contain 4, 
suggesting that the extra cysteine provides one more acylation site which contributes 
to lipid raft association (120). In mast cells, phospho-SNAP-23 is also enriched in 
lipid rafts upon activation (99). While we have not confirmed a similar distribution for 
phospho-SNAP-23 in platelets, is seems possible that raft association may have 
several positive effects on SNAREs and SNARE complex formation by concentrating 
both SNAREs and SNARE-regulators. Together, acylation may play a positive role in 
the redistribution of proteins into lipid rafts in platelets. Whether lipid rafts are 
potential fusion sites for platelet exocytosis will require further experimentation. 
Other Factors Affecting Raft Association: As discussed above, acylation aids 
protein localization to lipid rafts. Different acyl species may differentially affect this 
process. Given the turnover of acyl groups demonstrated in this dissertation it seems 
possible that dietary fatty acids could affect platelet function through their 
incorporation into the two t-SNAREs. Availability of fatty acids could also change the 
properties of the rafts through their incorporation into lipids. Lipid rafts are detergent–
resistant membrane domains consisting of cholesterol and sphingolipids in outer 
leaflet. In the inner leaflet, there are mainly saturated fatty acyl chains (221). 
Polyunsaturated fatty acids (PUFAs) are also detected in lipid rafts (221). PUFAs 
from dietary sources, such as omega-3s, inhibit platelet aggregation and activation 
(222-224). Liang et al. showed that PUFA displaced Fyn protein from lipid rafts in 
Cos-1 and Jurkat cells, although it remained membrane-associated (225). Unsaturated 
fatty acids may cause displacement of proteins from rafts since it is difficult to pack 
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the bulky side chains into the ordered lipid rafts domains (226). Alternatively, Stulnig 
et al. showed that PUFA change the composition of lipid rafts, especially inner 
leaflets, causing displacement of acylation protein from membrane rafts. In these 
studies, PUFAs were incubated with Jurkat T cells and the concentration PUFA, in 
raft fractions, increased significantly. Palmitated proteins, Lck and LAT, were 
displaced from membrane rafts after PUFA treatment. The determining factor for 
acylated protein association with rafts appears to be due to altering raft composition, 
not protein acylation with PUFAs. Acylation with PUFA appears to have a lower 
turn-over rate compared to that of acylation with palmitate (225,227,228). It is unclear 
whether PUFA can change inner leaflet of lipid raft composition causing t-SNARE 
raft association or not. Whether PUFAs affect protein acylation and or alter membrane 
raft composition in platelets and further affects t-SNARE redistribution will required 
further experimentation. 
Physiological Changes in Acylation: Both syntaxin-11 and SNAP-23 lack TMDs, 
but are acylated and, behave as integral membrane proteins. Lipid groups attached to 
cysteine-rich region of endogenous acylated proteins are diverse. While palmitate 
(C16:0) may be the major added fatty acid others, such as stearate (C18:0) and oleate 
(C18:1) could also be incorporated (229). The fatty acids released from other acylated 
platelet proteins have been analyzed by gas chromatography-mass spectrometry (230). 
The average compositions of lipids bound to proteins by thioester linkage are: 74% of 
palmitate, 22% stearate, and 4% oleate in inactivated platelets. When platelets were 
incubated with exogenous fatty acids, the lipid profiles changed, indicating that the 
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composition of extracellular lipids affects lipid profiles in platelets (230). Consistently, 
Fyn could be acylated with unsaturated fatty acids when Cos-1 cells were incubated 
with [
3
H]oleic acid (18:1), or [
3
H]arachidonic acid (20:4), but the efficiency of 
labeling is lower than that seen with [
3
H] palmitic acid (16:0) (225). When platelets 
were incubated with 17-Octadecynoic acid (17-ODYA) for 2 hr, however, 17-ODYA 
incorporation into syntaxin-11 and SNAP-23 could not be detected (data not shown). 
Other fatty acids were not tested however it should be noted that incubating platelets 
with Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) did negatively 
affect [
3
H] palmitic acid incorporation (data not shown) suggesting that they could be 
competitors for palmitoyl-CoA in the platelet Acyl-CoA pools Overall, there may be 
in the thioester-linked fatty acids attached to the platelet t-SNAREs, but further 
experiments will be required to determine if this heterogeneity is important for 
function. One step toward addressing this point is to determine the heterogeneity of 
acyl-CoA species present in platelets; this can be done mass spectrometry-based 
lipidomics. 
Summary: The work presented in the dissertation show that the post-translational 
modifications, phosphorylation and acylation, are important for granule secretion in 
platelets. As primary t-SNARE, SNAP-23 can be phosphorylated and acylated at the 
same time. SNAP-23 phosphorylation at Ser95 enhances membrane fusion. It is the 
first data to directly show that IKKβ is the enzyme that controls SNAP-23 and affects 
SNARE complex formation. Together with our in vivo studies of IKKβ, the current 
work elucidates a picture that IKK is required for platelet secretion through SNAP-23 
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phosphorylation. IKK inhibitors may be repurposed for controlling platelet function 
and treatment of cardiovascular diseases. A similar tack may be possible with 
acylation. Inhibitors of acylation and deacylation were used to show that acylation is 
dynamic and essential for platelet function. Acylation of t-SNAREs is important for 
granule secretion. Palmostatin B, as a deacylation inhibitor, can keep acylation on and 
counteract the effect of cerulenin, which may be used for controlling platelet secretion. 
Due to the insufficient number of specific inhibitors, further pharmaceutical design is 
required to develop better inhibitors for regulating syntaxin-11 and SNAP-23. Overall, 
post-translational modification of SNAREs, together with regulatory proteins 
regulates granule secretion from several steps as shown in Figure 5-3, especially for 
the fusion step. 
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Figure 5-1 S-Acylation is a Reversible Process 
S-acylation is a reversible process, regulated by acyl-protein thioesterase and 
palmitoyl acyltransferase respectively. In platelets, syntaxin-11 and SNAP-23 are two 
acylated proteins and essential for membrane fusion. Acylation state (red color 
labeled fatty acid) and deacylation state (grey color labeled fatty acid) 
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Figure 5-2 Acylation Affects the Role of t-SNARE in Platelet Secretion 
Primary t-SNAREs, syntaxin-11/SNAP-23, lack of integral membrane domain and 
acylation modifications provide hydrophobic anchors and help them associate with 
plasma membrane. Acylation makes SNARE-mediated membrane fusion more 
effeciently and may localize it into lipid raft region upon platelet activation. 
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Figure 5-3 Steps in Platelet Granule Secretion  
Secretory vesicles are targeted to active sites at the plasma membrane and 
subsequently they go through docking, priming, and fusion steps. During the process, 
these steps likely involve structural rearrangement between SNAREs and regulatory 
proteins. Phosphorylation of SNAP-23 may play a regulatory role in SNARE complex 
formation at steps. Acylation help t-SNAREs, lacking of TMD, to anchor to plasma 
membrane, and may also help them localize to lipid rafts for membrane fusion. 
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Appendices 
ABBREVIATIONS 
2BP 2-bromopalmitate  
5-HT Serotonin (5-hydroxytryptamine) 
aa  Amino acids 
ABE Acyl-biotinyl exchange 
ACD Acid citrate dextrose 
ADP  Adenosine diphosphate 
ApoE Apolipoprotein E 
APT  Acyl protein thioesterase 
ATP  Adenosine triphosphate 
BCA  Bicinchoninic acid 
Cerulenin  2,3 epoxy-4-oxo-7,10 dodecadienamide 
CHAPS 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate 
CMC Critical micellar concentration 
Compound V  2-(2-hydroxy-5-nitro-benzylidene)-benzo[b]thiophen-3-one 
DAG  Diacylglycerol 
DHA Docosahexaenoic acid 
DHHC  Asp-His-His-Cys 
DTT Dithiothreitol  
ECF  Enhanced chemifluorescence 
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EGF Epidermal growth factor 
ELISA  Enzyme-linked immunosorbent assay 
EM  Electron microscope 
EPA Eicosapentaenoic acid 
ER Endoplasmic reticulum 
FACS Fluorescent-activated cell sorting 
FBS Fetal bovine serum 
FGF Fibroblast growth factor 
FRET Förster resonance energy transfer 
GST Glutathione S-transferase 
FHL3 Familial hemophagocytic lymphohistiocytosis type 3 
FHL4 Familial hemophagocytic lymphohistiocytosis type 4 
FHL5  Familial hemophagocytic lymphohistiocytosis type 5 
FITC Fluorescein isothiocyanate 
GMFI Geometric mean fluorescence intensity 
HA Hydroxylamine  
HeLa cells Human epithelial cells 
HRP Horseradish peroxidase 
IAA Iodoacetamide 
IKK IκB kinase 
IP  Immunoprecipitation 
IP3 Inositol tri-phosphate 
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IPTG  Isopropyl-beta-D-thiogalactopyranoside 
LAMP  Lysosomal associated membrane protein 
LDL Low density lipoprotein 
MβCD Methyl-β-cyclodextrin 
NBD-PE N-(7-nitro-2-1,3-benzoxadiazol-4-yl)-1,2-dipalmitoyl 
phosphatidylethanolamine 
NK  Natural Killer 
NRK Normal rat kidney 
OCS Open canalicular system 
PAGE  Polyacrylamide gel electrophoresis 
PAS Protein A-Sepharose 4  
PAT  Protein acyltransferase 
PC 1-palmitoyl-2-oleoyl phosphatidylcholine 
PDGF Platelet-derived growth factor 
PE 1-palmitoyl-2-oleoylphosphatidyl-ethanolamine 
PF4  Platelet factor IV 
PGI2 Prostaglandin I2 
PI3P  Phosphatidyl inositol tri-phosphate 
PKA  Protein kinase A 
PKC  Protein kinase C 
PMSF  Phenylmethanesulphonylfluoride 
PPT  Palmitoyl protein thioesterase 
125 
 
PRP  Platelet rich plasma 
PS 1,2-dioleoyl phosphatidylserine 
PVDF Polyvinylidene fluoride 
Rhodamine-PE N-(lissamine rhodamine B sulfonyl)-1,2-dipalmitoyl 
phosphatidylethanolamine 
RT  Room temperature 
SNAP-23  Synaptosome-associated protein of 23 kDa 
SNAP-25  Synaptosome-associated protein of 25 kDa 
SNAP-29  Synaptosome-associated protein of 29 kDa 
SNARE  Soluble N-ethylmaleimide-sensitive fusion protein attachment protein 
receptor 
STXBP5/Tomosyn-1  Syntaxin binding protein 5 
TCA  Tricholoracetic acid 
TLR Toll-like receptors  
TMD Transmembrane domain 
VAMP  Vesicle associated membrane proteins 
VEGF Vascular endothelial growth factor 
VWF  Von Willebrand factor 
WT Wild-type 
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